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ABSTRACT 
POLYMORPHISMS IN P21 (CODON 31) AND P53 (CODON 72): 
ASSOCIATION WITH BREAST CANCER SUSCEPTIBILITY 
IN THE TURKISH AND GREEK POPULATIONS 
 
Gülsen ÇOLAKOĞLU 
Ms. in Molecular Biology and Genetics 
Supervisor: Asst. Prof. Dr. Isık G. YULUĞ 
August 2003, 121 pages 
 
The aim of this study was to investigate the potential association of p53 codon 72 and/or p21 
codon 31 polymorphisms with increased susceptibility for breast cancer either independently 
or combined in the Turkish and Greek populations. A case-control study was conducted for 
both populations and the genotypes of the subjects were determined by PCR-RFLP (Turkish; 
p53 genotypes for 274 cases and 221 controls, p21 genotypes for 322 cases and 246 controls, 
Greek; p53 genotypes for 138 cases and 138 controls, p21 genotypes for 156 cases and 136 
controls were obtained). Binary logistic regression was used to analyze the data. Although 
the Greek study population alone did not give statistically significant results, the p53 codon 
72 Arg/Arg inheritance was found to be significantly associated with breast cancer 
susceptibility in the Turkish study population (OR=2.16; 95% CI=1.08-4.31) as well as in 
the combined population of Turkish and Greek subjects (OR=2.35; 95% CI=1.25-4.41). This 
association was further increased with increased BMI (OR=3.86; 95% CI=1.12-13.26) in the 
Turkish population but the result should be treated with caution because of the wide 
confidence interval. The inheritance of the combined p21 codon 31 Arg/Arg or Ser/Arg 
genotypes increased breast cancer susceptibility in the Turkish study population (OR=1.15; 
95% CI=0.75-1.76) although the result is not statistically significant. The most prominent 
result of this study is that there is an interaction between the p53 Arg72Arg and p21 
Arg31Arg or Ser31Arg genotypes for breast cancer susceptibility (OR=2.66; 95% CI=1.06-
6.66). These results let us to conclude that there is a strong association between the p53 
Arg72Arg genotype and breast cancer risk in the Turkish population and that the 
combination of high-risk allelic variants of both p53 and its downstream effector protein p21 
may have a role as a risk factor for breast cancer development.   
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ÖZET 
P21 (CODON 31) VE P53 (CODON 72) POLİMORFİZMLERİ: 
TÜRK VE YUNAN POPULASYONLARINDA MEME KANSERİ İLE 
 İLİŞKİSİ 
 
Gülsen ÇOLAKOĞLU 
 Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Yrd. Doç. Dr. Işık G. YULUĞ 
Ağustos 2003, 121 sayfa 
 
Bu çalışmanın amacı, Türk ve Yunan populasyonlarında, p53 kodon 72 ve/veya p21 kodon 
31 polimorfizmleri ile meme kanserine yatkınlık arasındaki olası ilişkiyi incelemekti. Her iki 
populasyon için hasta-kontrol çalışması yapıldı ve tüm örneklerin genotipleri PCR-RFLP 
yöntemi ile belirlendi (Türklerde; p53 genotipi için 274 hasta ve 221 kontrol, p21 genotipi 
için 322 hasta ve 246 kontrol, Yunanlılarda; p53 genotipi için 138 hasta ve 138 kontrol, p21 
genotipi için 156 hasta ve136 kontrol elde edildi). Verilerin değerlendirilmesi için ikili 
lojistik regresyon analizi yöntemi kullanıldı. Yunanistan populasyonu tek başına 
incelendiğinde, istatistiksel açıdan anlamlı bir sonuç bulunamamasına rağmen, Türk ve 
Türk-Yunan populasyonları birleştirildiğinde anlamlı sonuçlar elde edildi. p53 geninin 72. 
kodonunun Arg/Arg olması durumu meme kanseri riski ile önemli derecede ilişkiliydi (Türk: 
olasılıklar oranı OR=2.16; %95 güven aralığı (GA)= 1.08-4.31, Türk-Yunan: OR=2.35; 95% 
GA=1.25-4.41). Bu ilişki, vücut kütle indeksi yüksek Türk kadınları arasında incelenince, 
olasılıklar oranı önemli derecede artış gösterdi (OR=3.86; 95% GA=1.12-13.26). Ancak, bu 
sonuç değerledirilirken güven aralığının geniş olduğu dikkate alınmalıdır. p21 genini 
incelediğimizde ise, 31. kodonun Arg/Arg ya da Ser/Arg olmasının meme kanserine 
yakalanma olasılığını arttırdığı görülmüştür, ancak sonuç istatistiksel açıdan anlamlı değildir 
(OR=1.15; 95% GA=0.75-1.76). Bu çalışmanın belki de en çarpıcı bulgusu, p53 kodon 72 
Arg/Arg genotipini ve p21 kodon 31 Arg/Arg ya da Ser/Arg genotiplerinden birini aynı anda 
taşıyan bireylerin meme kanseri riskinin artmasıdır (OR=2.66; 95% GA=1.06-6.66). Sonuç 
olarak, Türk populasyonunda meme kanserine yakalanma riski ile p53 Arg72Arg genotipi 
arasında önemli bir ilişki olduğu ve de ayrıca her iki genin birlikte, belirtilen kodon 
polimorfizmlerinde yüksek risk genotiplerini taşımasının meme kanserine yakalanma riskini 
daha da arttırdığı söylenebilir. 
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1. INTRODUCTION 
 
1.1 . Cancer: A Loss of Normal Growth Regulation 
Various disease states can arise when the normal stability of the organization of 
tissues and organs is disturbed. A tumor or neoplasm (literally, “new growth”) is an 
example of such tissue in which the control of growth becomes defective. Neoplasms 
can be defined as benign or malignant based on their likelihood of spreading. 
Encapsulated nodules of neoplastic tissue that do not spread are called benign 
tumors. On the other hand, malignant tumors often invade neighboring tissues and 
even other parts of the body, and thus may become lethal. Cancer is the common 
term for a malignant tumor. The word is from the Latin term for “crab” because early 
physicians noticed certain cancers had a crablike appearance (Becker et al. 1996).  
 
1.1.1. Neoplastic Transformation and Tumor Progression 
In most cases, malignant tumors develop from a single progenitor cell. The 
progenitor cell has undergone a series of irreversible (permanent and heritable) and 
cumulative changes in a process called neoplastic transformation. There are two 
general characteristics of the transformed cells: they undergo uncontrolled growth 
and tend to spread. The spread of cancer cells to neighboring tissues is called 
invasion; the spread to distant organs is called metastasis. The term metastases is 
used to refer to the tumor nodules that implant at sites distant from the parent tumor 
(Becker et al. 1996). 
Tumor progression is the incremental development of increasingly malignant 
characteristics by a tumor. Typically, tumors are relatively benign, slowly growing, 
weakly invasive or noninvasive in the early stages of development. With time, 
however, they can enter a phase of increasingly rapid growth and become highly 
invasive and metastatic. 
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1.2. Molecular Genetics of Cancer 
Cancer is a genetic disease resulting from mutations in somatic cells (Alberts et al. 
2002). Several lines of evidence indicate that tumorigenesis in humans is a multistep 
process and that these steps reflect genetic alterations that drive the progressive 
transformation of normal human cells into highly malignant derivatives (Hanahan et 
al. 2000).  
 
1.2.1. Genomic Integrity 
Genomic instability, which results in an elevated mutation rate, is a fundamental 
prerequisite of tumorigenesis  (Schmute et al. 1999). Some cancer cells are defective 
in the ability to repair local DNA damage or to correct replication errors that affect 
individual nucleotides. These cells tend to accumulate more point mutations than do 
normal cells. Other cancer cells cannot maintain the integrity of their chromosomes 
properly and thus display gross abnormalities in their karyotype (Alberts et al. 2002).  
Cells must protect the integrity of their genome to avoid both the inheritance of 
deleterious mutations by daughter cells and the accumulation of mutations in genes 
that control cell proliferation. Although there are many safeguards in cells to protect 
the genomic integrity, cellular DNA is constantly bombarded by mutagens from 
endogenous and exogenous sources. DNA replication, gene transcription, DNA 
repair and cell cycle checkpoints must all interlink to promote cell survival following 
DNA damage and protect the integrity of chromosomes. A highly coordinated 
response to DNA damage is the activation of appropriate repair pathways and 
reversible arrest at cell cycle checkpoints. The cell cycle arrest gives time for repair 
to be completed (Levitt et al. 2002).  
The p53 protein, also known as the “guardian of the genome”, responds in several 
ways to DNA damage in the cell. p53 acts as a transcription factor, stimulating 
synthesis of a 21-kDa protein that inhibits cyclin-dependent kinase (Cdk)-cyclin 
complexes. This block stops the cell cycle when DNA damage has occurred, giving 
the cell time to repair the damage so that genetic errors are not passed on to daughter 
cells. If the repair fails, p53 can trigger the damaged cells to undergo apoptosis, or 
programmed cell death, before their genetic abnormalities are inherited. Recent 
evidence indicates that p53 also stimulates the DNA repair machinery, acting both 
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directly and indirectly through other proteins. Mutations in the p53 gene not only 
cause a lack of these protective effects but also stimulate abnormal cell growth 
(Becker et al. 1996). 
 
1.2.2. Cancer-Critical Genes 
All genes whose mutation may lead to cancer are cancer-critical genes (Alberts et al. 
2002). Figure 1.1 summarizes the pathways and genes involved in cancer (Hanahan 
et al. 2000). These genes are classified into two groups according to whether the 
dangerous mutations they contain are those that cause loss of function or those that 
lead to gain of function: oncogenes and tumor suppressor genes. 
 
Figure 1.1. Pathways in Cancer 
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1.2.2.1. Oncogenes 
Gain-of-function mutations of proto-oncogenes stimulate cells to increase their 
ability to proliferate, disseminate, and divide when they should not. These mutations 
have a dominant effect, and the mutant genes are known as oncogenes (Alberts et al. 
2002). There are different types of genetic alterations that can activate proto-
oncogenes to become  oncogenes. The gene may be altered by a small change in 
sequence such as a point mutation, by a large scale change such as partial deletion, or 
by a chromosomal translocation that involves the breakage and rejoining of the DNA 
helix. These changes can occur in the protein-coding region yielding a hyperactive 
product, or they can occur in adjacent control regions so that the gene is simply 
expressed at concentrations that are much higher than normal. Alternatively, the 
cancer-critical-gene may be over-expressed because extra copies are present due to 
gene amplification events caused by errors in DNA replication. 
Oncogenes influence (directly or indirectly) functions connected with cell growth 
(Lewin B. et al. 2000). They may function as growth factors (i.e. wnt1- related to 
wingless), growth factor receptors (i.e. c-erbB- EGF receptor kinase), G 
protein/signal transduction (i.e. c-ras- GTP-binding protein), intracellular tyrosine 
kinases (i.e. c-abl- cytosolic), serine/threonine kinases (i.e. c-raf- cytosolic), 
signaling proteins (i.e. vav- SH2 regulator), and as transcription factors (i.e. c-myc, c-
fos, c-jun). The common feature is that each type of protein is able to direct general 
changes in cell phenotypes, either by initiating or responding to changes associated 
with cell growth, or by changing gene expression directly. 
  
1.2.2.2. Tumor Suppressor Genes 
Tumor suppressor genes protect cells from dysregulated growth and division. Both of 
their alleles must be inactivated to observe a phenotypic effect. There are two types 
of tumor suppressor gene: ‘gatekeepers’ and ‘caretakers’ (Levitt et al. 2002). 
Gatekeeper genes act directly to regulate cell proliferation and are rate limiting for 
tumorigenesis. The retinoblastoma (Rb) and p53 genes are examples of gatekeeper 
tumor suppressors. Caretaker genes do not directly regulate proliferation but when 
mutated lead to accelerated transformation of a normal cell to a neoplastic cell. 
MSH2 is an example of a caretaker which functions as a repair gene and is well 
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characterized in hereditary non-polyposis colon cancer. There are many so-called 
chromosomal instability disorders (i.e. ataxia telangiectasia) in which germ-line 
mutations in a caretaker gene lead to both genome instability and a predisposition to 
cancer. This shows the importance of these genes in suppressing neoplastic 
transformation. 
Tumor suppressor genes act mostly in a recessive manner (Oesterreich et al. 1999). 
The classical inactivation of tumor suppressor genes is caused by chromosomal loss 
of one allele and mutation of the other remaining allele. Functional inactivation of 
tumor suppressor genes can also be caused by hypermethylation, increased 
degradation, or mislocalization.    
The most important tumor suppressor is p53, the cellular gatekeeper for growth and 
division. More than half of all human cancers have either lost p53 protein or have 
cells with p53 mutations (Lewin et al. 2000). The p53 mutations fall into the 
category of dominant negative mutations, and the mutants function by overwhelming 
the wild-type protein and preventing it from functioning. The most common form of 
a dominant negative mutant is one that forms heteromeric protein containing both 
mutant and wild-type subunits, in which the wild-type subunits are unable to 
function. p53 exists as a tetramer. When mutant and wild-type subunits of p53 
associate, the tetramer takes up the mutant conformation. The stability of p53 is 
another important parameter as it usually has a short half-life. The response to DNA 
damage stabilizes the protein and transactivates it. The cellular oncoprotein Mdm2 
inhibits p53 activity. p53  induces transcription of Mdm2, so the interaction between 
p53 and Mdm2 forms a negative feedback loop in which the two components limit 
each other’s activities (Lewin  et al. 2000). 
 
1.3. Cell Cycle Regulation and Cancer 
An important component in the maintenance of the genome is the coordination and 
control of DNA replication, repair, and the distribution of DNA to daughter cells 
during each division cycle. Regulation at two stages of the cell cycle is critical in 
response to DNA damage: G1-S and G2-M boundaries. Cells delay cell cycle 
progression in order to facilitate the repair of DNA damage and to ensure that 
previous steps in the cell cycle are complete before proceeding (Kastan et al. 1997).   
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The p16-cyclin D1-cdk4-Rb pathway is central to the regulation of the G1-to-S phase 
transition and to the understanding of human cancers (Figure 2) (Levine et al. 1997). 
One of these four genes is altered or mutated in nearly every cancer examined. p16 is 
a negative regulator of cyclin D1-Cdk4, and the gene is heavily methylated in some 
cancer cells and mutated in other cancers. Cyclin D1 is amplified and over-expressed 
in a number of cancers (about 16% of breast cancers), and cdk4 mutations (no longer 
sensitive to p16) and gene amplifications have been reported in selected tumors. The 
retinoblastoma protein (Rb) is the major target of  cyclin D1-Cdk4 for cell cycle 
regulation and is also present in a mutant form in a number of cancers (such as small-
cell lung cancer and osteosarcomas). The Rb protein regulates E2F-DP transcription 
factor complexes (E2F-1, -2, and –3, and DP-1, -2, and -3), which in turn regulate a 
number of genes (including those encoding cyclin E, cyclin A,  and proliferating cell 
nuclear antigen) required to initiate or propagate the S phase of the cell cycle. 
Phosphorylation of Rb by cyclin D1-Cdk4 releases E2F-DP proteins from the Rb 
complex, relieving repression of these genes or activating their transcription. The Rb 
protein regulates the restriction point or start, as a “go- no go” signal for cell cycle 
progression that is sensitive to the impact of various growth factors (via the 
regulation of cyclin D1-Cdk4 and possibly p16). 
In response to some forms of DNA damage, p53 is activated and turns on the 
transcription of one of its downstream genes, p21 (WAF1, Cip-1), for G1 arrest of the 
cell cycle. p21 binds to a number of cyclin and Cdk complexes: cyclin D1-Cdk4, 
cyclin E-Cdk2, cyclin A-Cdk2, and cyclin A-cdc2. One molecule of p21 per complex 
permits Cdk activity (and may even act as an assembly factor), while two molecules 
of p21 per complex inhibit kinase activity and block cell cycle progression. p21 also 
binds to PCNA (Proliferating Cell Nuclear Antigen) (at its C-terminal domain). The 
available evidence suggests that p21-PCNA complexes block the activity of PCNA 
in DNA replication, but not its activity in DNA repair. Thus, p21 can act on cyclin-
Cdk complexes and PCNA to stop DNA replication (Levine et al. 1997).    
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Figure 1.2. Schematic Representation of Cell Cycle Regulators 
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1.4. Breast Cancer 
1.4.1. Clinical Information 
1.4.1.1. Incidence and Mortality  
Breast cancer is the most common malignancy in women and constitutes 18% of all 
cancers in women (Haimov-Kochman R. et al. 2002). Approximately 183,000 
women are diagnosed with invasive breast cancer each year and nearly 41,000 
women die of the disease (DeVita et al. 2001). In women aged 40 to 55, breast 
cancer is the leading cause of all mortality.  
 
1.4.1.2. Histopathology 
Breast carcinoma arises from the epithelium of the mammary gland, which includes 
the milk-producing lobules and the ducts that carry milk to the nipple. Malignant 
transformation of the stromal, vascular, or fatty components of the breast is not 
included in this definition and is extremely rare. There is increasing evidence that the 
breast epithelium undergoes a transformation from normal to hyperplasic, followed 
by the appearance of atypia in association with hyperplasia, ultimately becoming 
malignant. Malignant cells continue to evolve from noninvasive carcinoma, typified 
by ductal carcinoma in situ, to invasive carcinoma, and ultimately, to cells with 
metastatic potential (Vogelstein et al. 2002). 
The treatment and prognosis of a woman with breast cancer are strongly influenced 
by the stage at the time of diagnosis. Multiple staging systems have been proposed, 
but the most commonly used system is the one adopted by both the American Joint 
Committee and the International Union against Cancer. This staging system is a 
detailed TNM (tumor, nodes, metastasis) system but can be summarized as; Stage 0 
(carcinoma in situ), Stage I (tumor ≤ 2 cm, negative axillary nodes), stage II (tumor 
size 2-5 cm and/or mobile positive axillary nodes), Stage III (tumor size > 5 cm 
and/or fixed axillary nodes; inflammatory breast cancer), Stage IV (distant 
metastases beyond ipsilateral axillary nodes) (Vogelstein et al. 2002). 
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1.4.1.3. Risk Factors 
Multiple factors are associated with an increased risk of developing breast cancer, 
including increasing age, family history, exposure to female reproductive hormones 
(both endogenous and exogenous), dietary factors, benign breast disease, and 
environmental factors (DeVita et al. 2001).  
Family history of breast cancer: The best studied and most significant risk factor is 
family history of breast cancer.   Shared exposure to another risk factor cannot be 
excluded, but this most commonly represents heritable factors that increase the 
likelihood of developing breast cancer. The breast cancer susceptibility genes 
BRCA1 and BRCA2 represent the most dramatic examples, but since they account 
for only 15 to 20 percent of the breast cancer cases that cluster in families, other less 
penetrant but more common heritable factors are also considered (Vogelstein et al. 
2002). The risk of developing breast cancer is increased 1.5- to 3.0- fold if a women 
has a mother or sister with breast cancer. Family history, however, is a 
heterogeneous risk factor and depends on the number of relatives with breast cancer, 
the exact relationship, the age of diagnosis, and the number of unaffected relatives.  
Exposure to female reproductive hormones: The development of breast cancer in 
many women appears to be related to female reproductive hormones. 
Epidemiological studies have consistently identified a number of weaker breast 
cancer risk factors, each of which is associated with increased exposure to 
endogenous estrogens. Early age at menarche, nulliparity or late age at first full term 
pregnancy, and late age at menopause increase the risk of developing breast cancer 
(DeVita et al. 2001).  
Age at menopause: In postmenopausal women, obesity and hormone therapy, both 
of which are positively correlated with plasma estrogen and estradiol levels, are 
associated with increased breast cancer risk. The age specific incidence of breast 
cancer increases steeply with age until  menopause. After menopause, although the 
incidence continues to increase, the rate of increase decreases to approximately one-
sixth of that seen in the premenopausal period. This dramatic slowing of the rate of 
increase in the age specific incidence curve suggests that ovarian activity plays a 
major role in the etiology of breast cancer (DeVita et al. 2001). The relative risk of 
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developing breast cancer for a women with natural menopause before age 45 is one-
half that of a woman whose menopause occurs after age 55.    
Age at menarche and the establishment of regular ovulatory cycles are strongly 
linked to breast cancer risk. Earlier age at menarche is associated with an increased 
risk of breast cancer; there appears to be a 20% decrease in breast cancer risk for 
each year that menarche is delayed. 
Regarding menarche and menopause, it seems that the total duration of exposure to 
endogenous estrogen is an important parameter in breast cancer risk. 
Pregnancy: The relationship between pregnancy and breast cancer risk appears more 
complicated. Age at first full term pregnancy clearly influences breast cancer risk. 
Based on epidemiological studies, women whose first full term pregnancy occurs 
after age 30 have a two- to fivefold increase in breast cancer risk in comparison with 
women who have their first full term pregnancy before approximately age 18. 
Additionally, terminal differentiation of breast epithelial cells does not occur until 
the onset of lactation after the completion of a full term pregnancy. This final stage 
of differentiation may confer increased resistance to carcinogens (Vogelstein et al. 
2002). 
Body mass index (BMI; kg/m2): Many studies have examined breast cancer in 
relation to body weight, height, and overall body size (BMI) (Wrensch et al. 2003). 
Most case-control and cohort studies of increased height, a variable highly correlated 
with age at menarche, and risk of breast cancer suggest a positive relationship 
(DeVita et al. 2001, Brinton et al. 1992).  Although being overweight (high BMI) 
during early adult life has been associated with a lower incidence of premenopausal 
breast cancer (Wrensch et al. 2003, Brinton et al. 1992, Franceschi et al. 1996), 
weight gain after age 18 is associated with a significantly increased risk of 
postmenopausal breast cancer. The protection conferred by increased weight early in 
life is thought to be secondary to increased irregularity of menstrual cycles in these 
women, suggesting their exposure to endogenous estrogens is decreased. The 
increased risk with weight gain in later adult life has been explained by increased 
estrogen levels in these women secondary to increased production in adipose tissues 
(DeVita et al. 2001).   
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1.4.2. Genetics of Breast Cancer 
Breast cancer is a complex and heterogeneous disease caused by the interaction of 
both genetic and non-genetic factors. BRCA1 and BRCA2 are the two high 
penetrance breast cancer genes. Breast cancer in families with germ-line mutations in 
these genes appears as an autosomal dominant trait. In addition, mutations in several 
other genes such as TP53, MSH2, and PTEN have been identified as rare causes of 
hereditary breast cancer. It is very likely that other lower-penetrance genes, whose 
susceptibility inheritance pattern does not fit the classic model of Mendelian 
inheritance, are also responsible for inherited susceptibility to breast cancer. The 
presence of breast cancer susceptibility genes is directly responsible for 5 to 10 
percent of all breast cancers (Vogelstein et al. 2002). 
Breast cancer due to inherited susceptibility has several distinctive clinical features: 
age at diagnosis is considerably lower than in sporadic cases, the prevalence of 
bilateral breast cancer is higher, and the presence of associated tumors in affected 
individuals is noted in some families. Associated tumors may include ovarian, colon, 
prostate, and endometrial cancers and sarcomas. However, breast cancer due to 
inherited susceptibility does not appear to be distinguished by histologic type, 
metastatic pattern, or survival characteristics (Vogelstein et al. 2002). 
Table 1.1 summarizes the inherited defects in somatic genes responsible for 
hereditary and familial breast cancers (DeVita et al. 2001). 
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Table 1.1. Major Genetic Defects in Breast Cancer 
 
ESTABLISHED FAMILIAL BREAST GENES (ALL TUMOR SUPPRESSORS) 
Gene Chromosomal location Disease 
TP53 (p53) 17p13 (mutated, LOH) Li-Fraumeni syndrome of multiple hereditary cancers 
PTEN 10q23 (mutated, LOH) Cowden’s syndrome of multiple hereditary cancers 
BRCA-1 17q21 (mutated, LOH) Familial female breast and ovarian cancers 
BRCA-2 13q14 (mutated, LOH) Familial female and male breast cancers 
ESTABLISHED BREAST CANCER PROGRESSION GENES 
Gene Chromosomal location Class Function 
C-ERBB2 17q12 Oncogene (amplified) Growth factor receptor subunit 
C-MYC 8q24 Oncogene (amplified) Cell-cycle/cell death regulator 
CCND1 (Cyclin D1) 11q13 Oncogene (amplified) Cell-cycle G1 regulator 
CDKN2 (p16) 9p21 Suppressor gene (methylated, LOH) Cell-cycle G1 regulator 
RB-1 13q14 Suppressor gene (mutated, LOH) Cell-cycle G1 and G1/S regulator 
TP53 (p53) 17p13 Suppressor gene (mutated, LOH) 
Cell-cycle/cell death/DNA repair 
regulator 
CDH1 (E-cadherin) 16q22-23 Suppressor gene (methylated, LOH) Cell-cycle adhesion protein 
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Another approach to understanding the pathogenesis of breast cancer is the study of 
non-inherited (sporadic) breast cancers. This is an important complementary 
approach to the study of germ-line alterations for several reasons. First, the large 
majority of breast cancers do not arise as a result of inherited mutations in a single 
breast cancer susceptibility gene, and sporadic tumors may have fundamental 
molecular genetic differences. Second, genes that are frequently dysregulated or 
mutated in sporadic breast cancer are candidate genes for susceptibility loci. Third, 
the study of genetic alterations, such as mutations, deletions, and amplifications, 
provides clues to the mechanisms that result in the genomic instability in cancer 
cells. A summary of the genes altered in sporadic breast cancers is given in Table 
1.2. 
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Table 1.2. Somatic Alterations in Breast Cancer 
 
Gene/Region Modification Frequency 
Growth factors and receptors 
EGFR Overexpression  20-40% 
HER-2/neu Overexpression  20-40% 
FGF1/FGF4 Overexpression  20-30% 
TGFα Overexpression  Not reported 
Intracellular signaling molecules 
Ha-ras Mutation 5-10% 
c-src Overexpression 50-70% 
Regulators of cell cycle 
TP53 Mutation/inactivation 30-40% 
RB1 Inactivation 20% 
Cyclin D Overexpression 35-45% 
TGFβ Dysregulation Not reported 
Adhesion molecules and proteases 
E-cadherin Reduced/absent 60-70% 
P-cadherin Reduced/absent 30% 
Cathepsin D Overexpression 20-24% 
MMPs Increased expression 20-80% 
Other genes 
bcl-2 Overexpression 30-45% 
c-myc Amplification 5-20% 
nm23 (NME1) Decreased expression Not reported 
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1.4.3. Single Nucleotide Polymorphism Analysis and Importance 
Complex diseases do not follow a simple Mendelian mode of inheritance and  
frequently have an environmental component of causation. Many genes seem to be 
involved with comparatively low individual impact but, nevertheless, have 
considerable overall contribution. To understand the genetic contribution to the 
etiology of complex diseases, model calculations for detection of genes or alleles 
with modest effect use the approach called “association study” by geneticists or 
“case-control study” by epidemiologists (Becker et al. 2003). 
The original Mendelian view of the genome classified alleles as either wild-type or 
mutant. Subsequently multiple alleles, each with a different effect on the phenotype 
were recognized. In some cases it may not even be appropriate to define any one 
allele as “wild-type”. The coexistance of multiple alleles at a locus is called genetic 
polymorphism (Lewin et al. 2000). An allele is usually defined as polymorphic if 
multiple alleles exist as stable components and if it is present at a frequency of >1% 
in the population.  An SNP (single nucleotide polymorphism) marker is just a single 
base change in a DNA sequence, with an alternative of two possible nucleotides at a 
given position (Vignal et al. 2002). Although in principle any of the four possible 
nucleotide bases can be present at each position of a sequence stretch, SNPs are 
usually biallelic in practice. In every 1000 bases along the human chromosomes, on 
average approximately one nucleotide position is estimated to differ between any two 
copies of that chromosome (Landegren et al. 1998).  
There are different reasons why SNPs are currently utilized in epidemiological 
studies. One is their use in genome-wide scans as markers for disease genes. Another 
reason is the interest in allele-specific variation on the population level introduced by 
functionally relevant SNPs or by susceptibility loci in close linkage with them 
(Becker et al. 2003). In this instance, it is usual to start with candidate genes whose 
functional relevance for a disease is known or strongly assumed; and to consider 
several genes along well-established functional pathways, since most likely more 
than a single gene is associated with the disease. 
There recently has been a shift away from monogenic disorders toward the analysis 
of complex multifactorial diseases such as osteoporosis, diabetes, cardiovascular and 
inflammatory diseases, psychiatric disorders and most cancers, which occur at a 
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much higher frequency than single gene disorders. There is also increasing interest in 
the genetics of drug response (pharmacogenetics), an understanding of which may 
allow the ‘tailoring’ of therapies on an individual basis (Gray et al. 2000). The 
broadly familial nature of complex diseases clearly indicates a significant genetic 
component. However, in contrast to monogenic conditions, this genetic element is 
comprised of multiple gene variants each contributing a small effect. The extent of 
this problem is likely to be so great that the frequency of any polymorphism 
contributing to a disease phenotype will be only slightly elevated in a disease group 
compared with unaffected controls. Association studies with a large sample size, 
where cases of disease are compared with matched controls  from the same 
population, are likely to provide a greater opportunity to detect small effects. Single 
nucleotide polymorphisms (SNPs) are the most abundant and stable types of DNA 
sequence variation in the human genome due to low mutation rates. Many SNPs also 
have functional consequences if they occur in the coding or regulatory regions of a 
gene (Gray et al. 2000). The SNP markers have gained more and more popularity for 
their quick, accurate, and inexpensive properties for the genetic analyses of various 
diseases. The SNP markers provide a new method for identification of complex 
gene-associated diseases such as breast cancer (Hsieh et al. 2001). 
A handful of molecular strategies are in use for SNP analysis. All current methods 
involve target sequence amplification, and this is followed by distinction of DNA 
sequence variants by short hybridization probes or by restriction endonucleases, 
discrimination of mismatched DNA substrates by polymerases or ligases, or by 
observing the template-dependent choice of nucleotide incorporated by a polymerase 
(Landegren et al. 1998). 
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1.4.4. Genetic Polymorphism and Breast Cancer 
Breast cancer is a clinically heterogenous disease, as evidenced by the widely 
variable morphological appearance and distinctive gene expression profiles. Because 
of possible effects on protein function or expression, it is reasonable to suspect that 
polymorphisms in genes involved in carcinogen metabolism, estrogen production, 
DNA repair and cell-cycle control could predispose individuals to the development 
of breast cancer, as well as influencing the clinical phenotype of the tumor. Genetic 
variants associated with an amino acid change can obviously have consequences for 
protein function, while those that occur in promoter or intronic regions could alter 
the level of gene expression. Alternatively, the genetic variant may have no direct 
functional implications but could be linked to other polymorphisms that have altered 
functions relative to the wild-type sequence (Powell et al. 2002).  
Although 10-15% of breast cancer cases have some family history of the disease, 
only 5% can be explained by rare, highly penetrant mutations in genes such as 
BRCA1 and BRCA2. First degree relatives of breast cancer patients have a two-fold 
increase in risk over the general population, most of which cannot be accounted for 
by BRCA1 or BRCA2 (Dunning et al. 1999). Apart from shared environmental 
factors, the remaining familial risk may be due to common, low-penetrance genetic 
variants that are also referred to as modifier genes. Modifier genes have subtle 
sequence variants or polymorphisms that are associated with a small to moderate 
increased relative risk for breast cancer. Such variants are relatively common in the 
population and may be associated with a much greater proportion of breast cancer 
risk as a whole than the rare high penetrance genes (Weber et al. 2000).  
There are different ways of presenting gene polymorphism data in relation to breast 
cancer risk, depending on the nature of the polymorphism. In the case of simple 
biallelic polymorphisms, allele frequencies in cases and controls can be compared 
using the X2 test to ascertain statistical significance. However, this method does not 
produce an easily interpretable measure of the magnitude of breast cancer risk and 
also lacks statistical power compared with some alternatives (Dunning et al. 1999). 
A more appropriate method is to compare genotype frequencies of three possible 
genotypes among cases and controls. The relative risk of breast cancer for each 
genotype is then estimated by the odds ratio (OR). The baseline group is usually the 
common allele homozygotes, which by definition has an OR (and relative risk) of 1. 
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Depending on the allele frequencies, the number of rare allele homozygotes may be 
very small, particularly in small studies, and the associated OR will have a wide 
confidence interval. Under these circumstances, it is common to combine the 
heterozygotes and rare-allele homozygotes and calculate the rare-allele carrier OR. 
However, this risk estimate is valid only if the genetic model is dominant, an 
assumption that should not be made without appropriate evidence (Dunning et al. 
1999).  
Candidate low penetrance gene products have been chosen on the basis of biological 
plausibility, in that alterations in the protein would affect a pathway involved in 
carcinogenesis. Low penetrance candidates are found in a wide variety of pathways, 
ranging from the detoxification of environmental carcinogens to steroid hormone 
metabolism and DNA damage repair (Weber et al. 2000). Candidate modifier genes 
can be divided into three main groups: genes for proteins with roles in steroid 
hormone metabolism; genes coding for carcinogen metabolism enzymes; and 
common alleles of genes that have been identified through family studies such as 
TP53 and BRCA1. The candidate gene polymorphisms and their possible functional 
effects are listed in Table 3 (Dunning et al. 1999). The existence of low-penetrance 
genetic polymorphisms may explain why some women are more sensitive than others 
to environmental carcinogens such as replacement estrogens (Coughlin et al. 1999). 
Steroid hormone metabolism genes: Several factors, such as age at menarche, age at 
first pregnancy, number of pregnancies, and age at menopause alter exposure to 
endogenous hormones and many of these alter breast cancer risk. Hence, genes 
involved in the metabolism of sex hormones are strong candidates for breast cancer 
susceptibility genes. Those which take part in the sex hormone biosynthesis pathway 
may affect production of, and thus exposure to estradiol, the most active estrogen. 
Genes in this pathway include CYP17, CYP19, and the gene for 17β-hydroxysteroid 
dehydrogenase type 2. 
The bioavailability of hormones is partially controlled by catabolism, and catechol 
estrogens (2 hydroxy-estrogens) are the major breakdown products of estrogens. 
COMT is a phase II enzyme that methylates catechol-estrogens during their 
conjugation and inactivation. It has two forms: one membrane-bound and the other 
cytosolic; both are expressed in breast tissue and share a polymorphism associated 
with differences in methylation activity. 
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The sex hormones control the activation of responsive genes by first binding to 
specific receptors and forming complexes that can in turn bind to sequences in the 
promoters of downstream, hormone-responsive genes, such as Estrogen Receptor, 
Progesterone Receptor, and Androgen Receptor, which are candidates for breast 
cancer susceptibility genes (Dunning et al. 1999). The biological role of estrogens, 
including the growth and differentiation of normal mammary tissue, is mediated 
through the nuclear receptor protein (ER) that has an estrogen and DNA binding 
domains (Coughlin et al. 1999). 
Carcinogen metabolism genes: Several enzymes function in the detoxification of 
xenobiotic compounds, and their gene expression is induced in response to the 
presence of the compound (e.g. polycyclic aromatic hydrocarbons found in tobacco 
smoke). The actions of phase I and phase II enzymes make susceptible compounds 
more soluble and more readily excreted and consequently reduce cancer risk. 
However, the more soluble products of some compounds are even more potent 
carcinogens than the less soluble form. Hence, a genetic change that increases the 
expression of the gene or the activity of the protein produced may increase the 
amount of reactive carcinogen formed and, thus, increase the risk of cancer (Dunning 
et al. 1999). 
Two phase I enzymes, CYP1A1 and CYP2D6, are induced by, and act on, 
carcinogens found in tobacco smoke. Both have polymorphic differences in either 
inducibility or activity. CYP2E1, an enzyme that metabolizes ethanol, is also a 
candidate because epidemiological studies suggest that breast cancer risk is increased 
with alcohol consumption. 
The GST family are phase II enzymes that are potentially important in regulating 
susceptibility to cancer because of their ability to metabolize reactive electrophilic 
intermediates to usually less reactive and more water soluble glutathione conjugates 
(Mitrunen et al. 2001). For both GSTM1 and GSTT1, a high percentage of the 
Caucasian populations are homozygous for null alleles (up to 60 and 20%, 
respectively) and have no detoxifying GST activity. Levels of DNA adducts, sister-
chromatid-exchange, and somatic genetic mutations may be increased in carriers of 
GSTM1 and GSTT1 null genotypes (Dunning et al. 1999). 
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The N-acetyl transferases, NAT1 and NAT2, are also phase II enzymes, and  
metabolise aromatic amines, which are present in cigarette smoke and heterocyclic 
amines in cooked meats (Weber et al. 2000). However, the action of NATs on these 
carcinogens can produce electrophilic ions that may induce point mutations in DNA 
(Dunning et al. 1999). Aryl aromatic amines are mammary carcinogens whose rate 
of metabolic activation is determined by polymorphisms in NAT genes (Weber et al. 
2000). Polymorphism in both genes results in two phenotypes: slow acetylators who 
are homozygous for low-activity alleles, and fast acetylators who carry one or more 
high-activity alleles (Dunning et al. 1999). 
Common alleles of high-penetrance genes: Mutations in the TP53 and BRCA1 genes 
are associated with a high risk of breast and other cancers. Mutation in the TP53 
gene results in decreased p53 activity, which may lead to failure of cells with DNA 
damage to arrest and thus to continue to replicate with damaged DNA (Dunning et 
al. 1999). Polymorphisms in the p21 downstream component of p53 pathway are 
also described. In the case of BRCA1, where the protein function is still uncertain, 
the majority of confirmed mutations generate truncated proteins that are likely to 
have severely reduced activity. It has been hypothesized that amino acid substitutions 
outside the major functional domains may confer more moderate breast cancer risks. 
The majority of these substitutions are rare, and putative functional effects remain 
unconfirmed (Dunning et al. 1999). 
According to the recent review of published case-control studies, polymorphisms in 
CYP19, GSTM1, GSTP1 and TP53 appear to be stronger candidates for low-
penetrance breast cancer susceptibility genes, although they too need to be confirmed 
in larger studies (Dunning et al. 1999). 
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Table 1.3. Genetic Polymorphisms in Relation to Breast Cancer Risk 
Gene Base /Amino acid change Functional effect 
Steroid hormone metabolism genes 
COMT Exon 4 G → A/ Val158Met Reduced activity 
CYP17 Promoter T → C (T1931C)/ None Creates a fifth SpI site and might increase transcription 
CYP19 
Intron 4 (TTTA)u microsatellite/ None 
Intron 4 TCT insertion/deletion/ None 
Unlikely 
Unlikely 
CYP2D6 
2367delA (A allele)/ Frameshift 
Intron 3G → A (G1934A) (B allele)/ 
Premature stop at residue 544 
Del Lys281 (C allele) 
17.5-kb deletion (D allele) 
Nonfunctioning enzyme 
Nonfunctioning enzyme 
Catalytically normal enzyme, 
but wrong cellular compartment 
No enzyme 
EDH17B2 Exon 6 A → G/ Ser312Gly Unlikely 
ER 
CCC325CCG/ Pro325Pro 
Intron 1/exon 2 XbaI site 
None 
Unlikely 
PR Alu repeat insertion in introns G/ None Unlikely 
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Table 1.3. Continued 
Gene Base /Amino acid change Functional effect 
Carcinogen metabolism genes 
CYP1A1 
Exon 7 A → G (A4889G)/ Ile462Val 
3’ UTR T → C (T6235C)/ None 
Exon 7 C → A (C4887A)/ Thr461Asp 
3’ UTR T → C (T5639C)/ None 
Uncertain, possible increase in 
enzyme activity 
None 
Unknown 
None 
CYP2E1 Intron 6 unspecified/ None Unlikely 
GSTM1 Gene deletion Null individuals have no enzyme 
GSTP1 A313G/ Ile105Val Reduced enzyme activity 
GSTT1 Gene deletion Null individuals have no enzyme activity 
NAT1 A1088T/ None Possible increase in enzyme activity 
NAT2 
G191A 
C481T 
G590A 
G857A 
Low activity allele 
Low activity allele 
Low activity allele 
Low activity allele 
Other genes 
BRCA1 C2731T/ Pro871Leu Unknown 
BRCA1 G1186A/ Gln356Arg Unknown 
HSP70-2 1267/ Silent Unknown 
HSP70-
hom 2437/ Met493Thr Unknown 
TNF-α -308 G → A/ None Increased constitutive and inducible levels of TNF-α 
TP53 
Exon 3 G → C/ Arg72Pro 
16-bp insertion in introns 3/ None 
Intron 6 G → A/ None 
Unknown 
Unlikely 
Unlikely 
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1.4.4.1. p53 and p21 polymorphisms 
Polymorphisms in TP53 are considered candidate risk factors because of the very 
important role played by this gene in the maintenance of genomic integrity following 
genotoxic insult (Powell et al. 2002). Highly penetrant germline mutations in TP53 
are very rare, but polymorphisms are quite common and at least 14 polymorphisms 
have been described (Keshava et al. 2002). Five of these are in exons (codons 21, 36, 
47, 72, and 213), and 9 are in introns (intron numbers 1-3, 6, 7, and 9) (Keshava et 
al. 2002). Those investigated for association with breast cancer include a 16 bp 
insertion in intron 3, an Arg72Pro polymorphism in exon 4 and a single nucleotide 
polymorphism in intron 6. Only the codon 72 polymorphism appears to be 
significantly associated with the risk of breast cancer (Dunning et al. 1999). 
A major downstream component of the TP53 tumor suppressor pathway is the p21 
cyclin dependent kinase inhibitor, also known as WAF1 or CIP1 (Powell et al. 
2002).  It was initially thought that somatic mutations in this gene might be involved 
in tumor formation, particularly for cases having wild type TP53; however, p21 
mutations proved to be extremely rare in a variety of cancer types investigated 
(Powell et al. 2002). Polymorphisms in p21 have been described, with the two most 
common being Ser31Arg in exon 2 and a single nucleotide polymorphism in the 3’ 
untranslated region of exon 3, 20 bp downstream from the stop codon (Powell et al. 
2002). Another polymorphism, Asp149Gly, has also been reported in an Indian 
population (Powell et al. 2002). Interestingly, both codon 31 and 149 polymorphisms 
appear to occur more frequently in patients whose tumors contain wild type TP53 
(Powell et al. 2002). Another suspected p21 polymorphism occurs in the 5’ region of 
intron 2 but this remains to be confirmed (Powell et al. 2002).   
Su et al. (2003) reported that different p53 and p21 genotypes or their combinations 
are associated with an altered human gene expression of p21. The genotype 
combination involving both the p53 codon 72 Pro allele and the p21 codon 31 Arg 
allele is associated with a particularly low expression of p21. 
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1.4.4.1.1.  p53 Structure-Function Relationship and Polymorphism 
The p53 tumor suppressor gene is located at 17p13.1 and encodes a 53-kDa nuclear 
phosphoprotein whose primary role is to maintain genomic integrity through cell 
cycle arrest, DNA repair, and apoptosis. The protein consists of 393 amino acids that 
can be functionally divided into three domains (Figure 3, Ko et al. 1996). The NH2 
terminus (amino acids 1-95) controls the transactivational activity of the protein, the 
central region (amino acids 102-292) controls the DNA binding activity, and the 
COOH terminus (amino acids 300-393) is responsible for oligomerization, 
nonspecific DNA binding, and DNA damage recognition (Powell et al. 2000).  
 
Figure 1.3. Structural Organization of p53 Protein 
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Polymorphisms in TP53 are considered candidate risk factors because of the very 
important role played by this gene in the maintenance of genomic integrity following 
genotoxic insult (Powell et al. 2002). In human populations, the p53 gene has a 
common polymorphism at codon 72. The alleles of the polymorphism at codon 72 
(exon 4) are ‘G’ or ‘C’ at the nucleotide residue 347. When ‘G’ is present it encodes 
an arginine amino acid (CGC; Arg72) with a positive-charged basic side chain, when 
‘C’ is present it encodes a proline residue (CCC; Pro72) with a nonpolar-aliphatic 
side chain (Langerod et al. 2002). Matlashewski et al. (1987) concluded that this is a 
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nonconservative amino acid change, and results in a structural change in the protein, 
since the p53pro variant migrates more slowly than the p53Arg variant in sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). It was also noted 
that the tumors produced by the Pro-72 p53-containing cells appeared more slowly 
and were smaller than the Arg-72 p53 tumors. 
The polymorphism occurs in the proline-rich domain of p53, which is required for 
the growth suppression activity of p53 and also plays an important role in p53-
mediated apoptosis but not in cell cycle arrest (Thomas et al. 1999). This polyproline 
region is considered to be an Src homology 3 (SH3) binding domain, and the proline 
at amino acid 72 constitutes one of the five PXXP SH3 binding motifs defined within 
this region. As evidenced by monoclonal antibody reactivity, both proteins are 
structurally wild type, and they exhibit similar levels of affinity for a variety of p53 
DNA recognition sequences. However, there are subtle differences in their abilities 
to interact with basic elements of the transcriptional machinery, and this is reflected 
in differences in the abilities of each form to induce apoptosis and suppress 
transformed cell growth. p53-Pro is a stronger inducer of transcription than p53-Arg, 
whereas a p53 Arg/Arg genotype induces apoptosis with faster kinetics and 
suppresses transformation more efficiently than the p53 Pro/Pro genotype (Thomas 
et al. 1999).  
The proline-rich PXXP domain between residues 60-90 of p53 is required for 
cooperation with anti-neoplastic agents to promote apoptosis of tumor cells, while 
deleting the C-terminal 30 amino acids of p53 does not have any effect (Baptiste et 
al. 2002).   
E6 proteins from both high-risk and low-risk HPV types are able to target p53Arg 
more efficiently than p53Pro for ubiquitin-mediated degradation. Consistent with this 
observation, the majority of HPV-associated tumors are homozygous for the p53Arg 
allele, whereas the majority of the comparable normal population was heterozygous 
(Thomas et al. 1999). 
p53 codon 72 polymorphism influences the ability of certain conformational p53 
mutants to form stable complexes with p73. When codon 72 encodes Arg, the ability 
of mutant p53 to bind p73, to neutralize p73-induced apoptosis and to transform cells 
in cooperation with EJ-Ras is enhanced. Arg-containing allele was preferentially 
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mutated and retained in squamous cell tumors arising in Arg/Pro germline 
heterozygotes. Formation of such complexes correlates with a loss of p73 DNA-
binding capability, and consequently its ability to serve as a sequence-specific 
transcriptional activator and an inducer of apoptosis (Marin et al. 2000). 
Langerod et al. (2002) reported that in breast cancer cases, the occurance of a p53 
mutation was significantly more often found on the Arg72 allele than the Pro72 
allele. The observed skewed occurance of somatic p53 mutations on the Arg72 allele 
in breast carcinomas suggests that this combination gives breast epithelial cells a 
growth advantage, which may increase the risk of malignant transformation and 
development of cancer. The coexistance of the Arg72 with a mutation may modify 
the p53 protein structure in a way that interferes either with the protein’s ability to 
achieve sequence-specific binding to DNA or with the interaction and recruitment of 
the transcription machinery, causing an altered transcription pattern. Another 
possibility is that the Arg72 may modify the mutant p53 protein’s ability to bind to 
and interact with other proteins such as p73 (Langerod et al. 2002). 
p53 recessive mutants carrying the Arg allele can lead to decreased activation of p53 
target genes through inactivation of p73. The transdominant p53 mutants achieve this 
by inactivation of the remaining wild type p53 allele (Tada et al. 2001). 
For p53 mutants associated with human tumors, the arginine variant confers greater 
resistance to p73-dependent apoptosis and cytotoxicity than the equivalent proline 
form. This correlates with cellular resistance to the apoptotic and cytotoxic activity 
of specific cancer chemotherapeutic agents (Bergamaschi et al. 2003). 
In cell lines containing inducible versions of alleles encoding the Pro72 and Arg72 
variants, and in cells with endogenous p53, the Arg72 variant induces apoptosis 
markedly better than does the Pro72 variant. At least one source of this enhanced 
apoptotic potential is the greater ability of the Arg72 variant to localize to the 
mitochondria; this localization is accompanied by release of cytochrome c into the 
cytosol. The two polymorphic variants of p53 are functionally distinct, and these 
differences may influence cancer risk or treatment (Dumont et al. 2003).  
Using microsatellite analysis, the frequency of LOH at the TP53 locus was 
investigated in patients heterozygous for the codon 72 polymorphism and it was 
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determined that the Arg allele is preferentially retained in patients heterozygous for 
this polymorphism (Papadakis et al. 2002). 
There have been many studies conducted in order to investigate the association of 
p53 codon 72 polymorphism and cancer risk. While some of the results are 
significant, some of them show inconsistency. It is important to note that the results 
differ according to ethnicity. Table 1.5 summarizes some of the studies.       
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1.4.4.1.2.  p21 Structure-Function Relationship and Polymorphism 
Although p53 mutation is the most common genetic change reported in human 
cancers, about 50% of cancers do not have p53 mutations. Mutations or alterations 
on genes situated upstream or downstream of p53 on the same control pathway might 
have a similar oncogenic effect. Thus WAF1/CIP1 alterations could be good 
candidates to substitute for p53 mutations (Li et al. 1995). Table 1.4 summarizes 
some of the studies conducted so far in relation to p21 codon 31 polymorphism and 
cancer risk. 
The human p21waf1/cip1 localized to chromosome 6p 21.2 is a cyclin dependent kinase 
inhibitor (CDKI) upregulated by wild type tumor suppressor protein p53. Wild type 
p53 binds to a site 2.4 kb upstream of the p21 coding sequence and stimulates gene 
expression (Su et al. 2003). 
Loss of heterozygosity of the short arm of chromosome 6 where p21 is situated has 
been described in cases of colon, lung, ovary and renal cancers, suggesting that 
WAF1/CIP1 may be inactivated by a two-hits process in the corresponding tumors 
(Li et al. 1995). 
Mutations and deletions of the p21 gene have been rare in human cancers suggesting 
that p21, if involved in tumorigenesis, may be exerting itself mainly on the 
expression level rather than on the gene level (Bahl et al. 2000). However, p21 
polymorphisms have been observed in various cancers. The polymorphic variants 
have been reported to occur more frequently in cancer patients than in healthy 
individuals suggesting a role in increased susceptibility to the development of some 
types of cancers (Mousses et al. 1995). Moreover, the frequency of the CIP1/WAF1 
variants in tumors which contain p53 gene mutations was found to be significantly 
less than the frequency of the CIP1/WAF1 variants in tumors without p53 gene 
mutations. These data suggest that the variants at codon 31 and/or in the 3`UTR may 
not be benign polymorphisms, but may possibly be associated with a higher risk of 
developing cancer (Mousses et al. 1995). 
The WAF1/CIP1 gene consists of three exons of 68, 450 and 1600 bp and encodes a 
21 kDa protein of 164 amino acids (Figure 1.4). The first exon is non-coding while 
exon 2 contains 90% of the coding sequence (Li et al. 1995). The first ATG codon 
appears at nucleotide 76 in exon 2, and a termination codon appears at nucleotide 
 28 
570 in exon 3 (Ralhan et al. 2000). The unique ability to associate the proliferating 
cell nuclear antigen (PCNA), an auxiliary factor for DNA polymerase δ and ε, 
distinguishes p21 from other cyclin-dependent kinase inhibitors (CDKIs). The Cdk 
and PCNA inhibitory activities of p21 have been mapped to different domains of the 
protein. An N-terminal domain which binds and inhibits cyclin-Cdk complexes, and 
a short sequence near the C-terminus (between amino acid residues 144-151) which 
binds to PCNA results in the inhibition of DNA replication (Bahl et al. 2000).  
 
Figure 1.4. Representation of p21 Protein 
 
 
 
 
 
http://www.infobiogen.fr/services/chromcancer/Genes/CDKN1AID139.html 
 
The codon 31 polymorphism is found in an area of greater than 90% homology at the 
protein level with the murine homologue, which is thought to encode a DNA- 
binding zing-finger domain (Shih et al. 2000) in amino acids 13 and 41, and contains 
a potential nuclear localization signal between amino acids 140 and 163 (Hachiya et 
al. 1999). The sequences between amino acids 13 and 56 are almost perfectly 
conserved between mouse and human, and there is strong homology between WAF1 
and p27KIP1 protein, as well as p57KIP2 protein. This conservation of the amino acid 
sequences suggests that this region is important to the function of WAF1 as a CDK 
inhibitor (Hachiya et al. 1999). In addition, serine is an uncharged polar amino acid 
with a single hydroxy 1 side chain, whereas arginine is a basic, positively charged 
amino acid with a seven-membered side chain. These observations raise the 
possibility that this polymorphism encodes functionally distinct proteins. In fact, it 
has been reported that the Arg variant has been observed in a significant number of 
cancer cases (Hachiya et al. 1999). However, transfection studies have shown no 
difference in the tumor suppressor abilities of the Ser and Arg alleles in a lung cancer 
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cell line (Chedid et al. 1994). In addition , in vitro CDK-cyclin kinase assays have 
shown that wild type Ser-p21 and the variant Arg-p21 both have similar growth-
inhibitory abilities (Sun et al. 1995). Moreover, a tumor suppression assay using 
H1299 cells, which lack p53 protein expression, revealed no functional difference 
between the protein encoded by the codon 31 Ser and Arg alleles of the WAF1 gene 
(Hachiya et al. 1999). However, the assay used constructs which produced high 
levels of WAF1 protein constitutively. WAF1 induction is involved in a stress 
response to DNA damage via transcriptional modulation by p53. Thus, these assays 
would not reproduce the in vivo expression pattern of the WAF1 protein, as neither 
the cells nor the experimental conditions can be considered equivalent to those of the 
normal cellular environment. Experiments using endogeneous regulatory sequences 
of the WAF1 gene will be required to evaluate the functional difference between 
wild-type and variant proteins. 
Previous studies indicated a significant association of the Arg allele with human 
malignancies including breast tumor, sarcoma, rhabdomyosarcoma, neuroblastoma, 
prostate adenocarcinoma, colorectal cancer and lung cancer (Table 1.4). In those 
studies, the Arg allele was reported to occur more frequently in malignancy groups 
than in the healthy control, suggesting that the Ser to Arg substitution results in some 
functional differences which contribute to tumorigenesis (Konishi et al. 2000). 
The 3’ untranslated region of several genes has been shown to be a region important 
in cellular proliferation, differentiation, tumor suppression, and metastasis 
suppression. DNA sequences that determine mRNA stability and its rate of 
degradation exist in this region. Because the two p21 variants appear to segregate 
together, a synergistic mechanism may be involved in maintaining an altered cellular 
phenotype. The 3’ untranslated region polymorphism may be located at a site 
necessary for rapid p21 message degradation, the variant preventing its timely 
demise. The p21 mRNA containing the codon 31 variant may be rendered more 
stable because of its association with the 3’-UTR polymorphism. This altered 
message, with an extended half-life, may be sufficient to interfere with DNA 
damage-induced G1 cell cycle arrest and increase the sensitivity of cells to DNA 
damage. This may lead to the observed increase in cancer susceptibility for 
individuals carrying both polymorphisms, although these findings must await further 
confirmation by additional studies (Facher et al. 1997). 
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Probable differences in the p21 function between the Arg and Ser allelic products 
were also claimed by Sun et al. (1995), who reported that there was no significant 
difference between the two allelic products in their ability to inhibit CDK activity 
and tumor cell growth. Thus, the association between the Arg allele and the p21 
function is questioned. 
Although further investigations are required for clarifying the association of the p21 
polymorphism with tumorigenesis, it is important to take the ethnic differences of the 
allele frequency distribution into account when studying the role of the p21 
polymorphism in carcinogenesis (Konishi et al. 2000). The codon 31 polymorphism 
of p21 shows distinct differences among major ethnic groups. The frequency of Arg 
allele ranges from 4% in caucasians, to 16% in Indians, 29% in African Blacks in the 
USA, and 50% in Chinese (Shih et al. 2000). 
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Table 1.4.  p21 Codon 31 Polymorphism and Cancer Association 
 
Cancer Population # of cases 
# of 
controls Odds ratio (95% CI) Results Reference 
Breast  Caucasian 93 187 S/S; 1.10 (0.35-3.50) No association Keshava et al., 2002 
Breast      American 88 21 No correlation Lukas et al., 1997 
Breast African-American 37 65 S/S; 2.32 (0.66-5.60) Association 
Keshava et al., 
2002 
Breast Latinas 30 75 S/S; 2.22 (0.71-6.89) Association Keshava et al., 2002 
Breast      Caucasian 286 81 No association Powell et al., 2002 
Cervical (CIN 
III, SCCA, 
Adenocarcinoma) 
Korean 212 98 S/S; 3.59 (1.55-8.31) S/S significant in adenocarcinoma Roh et al., 2001 
Colorectal      French 45 70 No association Li et al., 1995 
Endometrial Taiwanese 102 119 R/R;  0.53 (0.25-1.14) No association Hsieh et al., 2001 
Endometrial Japanese 54 55 R/R; 2.52 (1.09-5.80) Arg allele associated, hypertension positive risk 
Hachiya et al., 
1999 
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Table 1.4.  Continued 
 
Cancer  Population # of cases 
# of 
controls Odds ratio (95% CI) Results Reference 
Endometrial     American 47 21
Association between 
increased p21 protein 
expression and 31 Arg 
allele 
Lukas et al., 
1997 
Head and neck 
carcinoma 
American 
(Pennsylvania) 
42  110
 Not significant, increased 
Arg allele frequency 
Facher et al., 
1997 
Lung   Swedish 144 761 R; 1.70 (1.00-2.90) Significant increase in Arg allele frequency 
Sjalander et al., 
1996 
Lung Caucasion 1069 1220 R/R; 0.85 (0.40-2.00) No association Su et al., 2003 
Lung Taiwanese 155 189 R; 1.15 (0.70-1.86) No association Shih et al., 2000 
Nasopharyngeal      Taiwanese 76 66 No association Sun et al., 1995 
Ovarian    American 53 21  No correlation Lukas et al., 1997 
Prostate 
adenocarcinoma 
American 
(Pennsylvania)  
54  110
 Not significant, increased 
Arg allele frequency 
Facher et al., 
1997 
Skin    Japanese 113 165  No association Konishi et al., 2000 
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Table 1.5.  p53 Codon 72 Polymorphism and Cancer Association 
 
Cancer Population # of cases 
# of 
controls Odds ratio (95% CI) Results Reference 
Acute Myeloid 
Leukemia Japanese     200 No association
Nakano et al., 
2000 
Bladder Slovakian 50 145 1.44 (0.82-2.27) No significance Biro et al., 2000 
Breast Caucasion/ Slavic  448 249 P; 0.96 (0.74-1.25) No association 
Suspitsin et al., 
2003 
Breast Greek 56 61  Arg/ Arg association Papadakis et al., 2000 
Breast    Caucasion 93 187 3.15 (1.14-8.89)
Association, stronger in 
postmenopausal breast 
cancer, no association 
with p21 codon 31 
polymorphism 
Keshava et al., 
2002 
Breast African-American 37 65 1.29 (0.54-3.10) No association 
Keshava et al., 
2002 
Breast     Turkish 115 76 Arg/Arg association Buyru et al., 2003 
Breast Latinas 30 75 0.52 (0.12-2.16) No association Keshava et al., 2002 
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Table 1.5. Continued 
 
Cancer Population # of cases 
# of 
controls Odds ratio (95% CI) Results Reference 
Cervical  Indian 85 29  Arg/Arg significant Nagpal et al., 2002 
Cervical      Korean 234 100 No association Kim et al., 2001 
Cervical Indian 232 189 1.12 (0.69-1.82) No association Pillai et al., 2002 
Cervical Indian 134 131 2.40 (1.89-3.04) Arg/Arg association Saranath et al., 2002 
Cervical  Israeli Jewish 23    162 Arg/Arg association
Arbel-Alon et al., 
2002 
Cervical  Chinese 15 20  Arg/Arg significant Qie et al., 2002 
HPV-associated 
malignancies- 
esophageal 
(HPV+, HPV-) 
Chinese   39 23
 
Arg/Arg significant Li et al., 2002 
HPV-associated 
malignancies- 
ovarian (HPV+, 
HPV-) 
Chinese   26 13
 
Arg/Arg significant Li et al., 2002 
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Table 1.5. Continued 
 
Cancer Population # of cases 
# of 
controls 
Odds ratio (95% CI) Results Reference 
HPV-associated 
malignancies- 
breast (HPV+, 
HPV-) 
Chinese     19 9 Arg/Arg significant Li et al., 2002 
Gastric cardia Caucasian 32 (non-cardia) 88 3.1 (1.4-7.3) Arg/Arg association Zhang  et al. 2003 
Gastric Japanese 117 116 2.98 (1.07-8.32) Pro/Pro association Hiyama et al., 2002 
Laryngeal tumors Greek 37 40  Arg/Arg association Sourvinos et al., 2001 
Lung  American 482 510 1.45 (1.01-2.06) 
Pro/ Pro association, 
Pro/Pro+Arg/Pro also 
associated, smoking 
increases the risk 
Fan et al., 2000 
Lung Greek 54 99 3.13 (1.46-6.73) Arg/Arg association Papadakis et al., 2002 
Lung Japanese 111 170  No association Pierce et al., 2000 
Lung Caucasian 138 173  No association Pierce et al., 2000 
Lung Hawaiian 85 103  No association Pierce et al., 2000 
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Table 1.5. Continued 
 
Cancer Population # of cases 
# of 
controls 
Odds ratio (95% CI) Results Reference 
Squamous Cell 
Carcinoma French 45 22  No association in men 
Humbey et al., 
2003 
Vulval cancer Caucasian 52 246  Lower risk with Arg/Arg Rosenthal et al., 2000 
Vulval 
intraepithelial 
neoplasia 
Caucasian 48 246  Lower risk with Arg/Arg Rosenthal et al., 2000 
Urothelial  Japanese 112 175 2.28 (1.12-4.66) 
No significance in men, 
Pro/Pro significant in 
smokers 
Kuroda et al., 
2003 
 
 
 37 
1.5. AIM 
The aim of this study is to test any possible association of the germline 
polymorphisms of either p21 codon 31 or p53 codon 72 with increased susceptibility 
for breast cancer either independently or combined in the Turkish and Greek 
populations. 
In this study, the questions to be answered are as follows: 
1. Does p53 codon 72 polymorphism constitute a risk for breast cancer 
development in the Turkish and Greek populations? 
2.  Does p21 codon 31 polymorphism constitute a risk for breast cancer 
development in the Turkish and Greek populations? 
3. Is there any relation between the established risk factors for breast cancer and 
the polymorphisms of p53 and p21 genes? 
4. Is there a combined effect of p21 and p53 polymorphisms for breast cancer 
susceptibility? 
We studied the two different populations separately, because both polymorphisms 
show considerable differences among populations with different ethnicity. 
The p53 codon 72 polymorphism was studied, since its role as a cancer risk factor 
was well established in different populations, but its effect on breast cancer was not 
analyzed thoroughly in the Turkish population.   
The p21 codon 31 polymorphism was studied, since contradictory results have been 
reported for various cancer types in various populations and its relation with breast 
cancer susceptibility is less well established. 
Analysis for any possible gene-gene interaction between the p53 and p21 
polymorphisms was included in this study because there have been no reports on the 
combined analysis of p53 codon 72 and p21 codon 31 polymorphisms in breast 
cancer although they are two critical components of the same pathway for cell cycle 
regulation.  
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2. MATERIALS AND METHODS 
 
2.1. MATERIALS 
 
2.1.1. Subjects 
Turkish and Greek populations were included in this study. The cases were female 
patients diagnosed with breast cancer while females with no history of (breast) 
cancer served as a control group. Blood samples were collected from each individual 
and used for genomic DNA preparation. 
 
2.1.1.1. Turkish Population  
Patients: The Turkish study population consisted of 386 cases (Table 2.1). Blood 
samples of 301 cases were obtained from Numune Hospital,  Ibni Sina Hospital, and 
Gazi University Medical School, Ankara. Genomic DNA was isolated from blood 
using the phenol-chloroform extraction method, which is described in Section 2.2.1.  
DNA for 85 of the breast cancer patients was obtained from Akdeniz University 
Medical School, Antalya. 
A standardized questionnaire form was used in order to get information about the 
subject’s age, weight, height, age at menarche, age at first full term pregnancy, 
smoking history, and family history of breast cancer (see; questionnaire form). 
 
Controls: 301 females, with no history of breast cancer, from Numune Hospital, Ibni 
Sina Hospital, and Gazi University Medical School, Ankara, were used as a control 
group (Table 2.1). Information about the subject’s age, weight, height, age at 
menarche, age at first full term pregnancy, smoking history, and family history of 
breast cancer were obtained from standardized questionnaire forms. 
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2.1.1.2. Greek Population 
180 breast cancer and 189 controls were included in this study (Table 2.2). The DNA 
samples from the Greek population were sent by Dr. Drakoulis Yannoukakos 
(Molecular Diagnosis Laboratory, National Center for Scientific Research, Athens, 
Greece). 
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HASTA ANKET FORMU 
 
1. Adı Soyadı: 
2. Yaşı: 
3. Medeni hali: 
4. Yaşadığı şehir ve süresi: 
5. Ağırlığı (kğ): 
6. Boyu (cm): 
7. Mesleği: 
8. İlk mestürasyon periyodunun başlama yaşı: 
9. Menapozal durumu: 
Premenapozal ise; son menstürasyon periyodunun kaç gün önce olduğu: 
Postmenapozal ise; son menstürasyon periyodunun kaç gün önce olduğu: 
10. Tanı konulduğu zamanki menapozal durumu: 
11. Tanının ne zaman konulduğu: 
12. Uygulanan tedavi: 
13. Daha öne hormon tedavisi gördümü? Ne tip? 
14. Oral kontraseptif kullandımı? Nedir? 
15. Kaç çocuğu var? 
a. İlk doğumunu yaptığı yaş? 
b. Son doğumunu yaptığı yaş? 
16. Daha önce meme ile ilgili operasyon geçirdi mi? 
17. Ooferektomi (yumurtalıkların alınması) yapıldı mı? Yapıldı ise kaç yıl önce? 
18. Sigara içme alışkanlığı: 
Hiç içmedim ( )   Eskiden içerdim ( ) 
1-10 sigara/gün ( )   11-20 sigara/gün ( )   20 ve daha fazla/gün ( ) 
1 yıldır içiyorum ( )   2-5 yıldır içiyorum ( )   5-10 yıldır içiyorum ( ) 
10-15 yıldır içiyorum ( )  15-20 yıldır içiyorum ( )  20 ve daha fazla yıldır içiyorum ( ) 
19. Sigara içilen ortamda sıkça bulunuyormusunuz? 
(a) Evet   (b) Hayır 
20. Alkol kullanıyormusunuz? 
(a) Evet   (b) Hayır 
Nadiren Haftada 1 kez Haftada 2-3 kez Haftada 4-5 kez Haftada 6-7 kez 
21. Beslenme alışkanlığınızda size en fazla uyan tanım aşağıdakilerden hangisidir? 
a. Kızartma ağırlıklı yağlı diyet 
b. Sebze ağırlıklı yağsız diyet 
c. Dengeli beslenme 
21. Radyasyona maruz kaldınız mı? Hangi sıklıkla? 
(a) Evet   (b) Hayır 
22. Tiroid ile ilgili bir rahatsızlığınız var mı? 
(a) Evet   (b) Hayır 
Hipertiroidizm ( )  Hipotiroidizm ( ) 
23. Aile bireylerinde ve sizde genetik bir rahatsızlık var mı? Tipi? 
(a) Evet   (b) Hayır 
24. Ailenizde meme kanserli başka bireyler var mı? (Anne, kardeş, anneanne, vb) 
(a) Evet   (b) Hayır 
25. Tümörün histopatolojisi 
26. Tümör grade 
27. Tümör stage 
28. Östrojen reseptör durumu (+) veya (-) 
29. Progesteron reseptör durumu (+) veya (-)    
Table 2.1. Selected Characteristics of Breast Cancer Patients and Age-matched Control Subjects in the Turkish Population 
 
 
Characteristics  Cases Controls
Age, n; mean (standard deviation) n=370; 49.30 (12.45) n=288; 46.59(14.42) 
Age, range 20-80  15-83
Family history of breast cancer, n; % n=297; 14.48% n=285; 2.46% 
Body mass index (BMI), n; mean (standard deviation) n=331; 27.267 (4.95) n=274; 27.399 (5.26) 
Age at first live birth, n; mean (standard deviation) n=318; 22.51 (5.14) n=244; 20.56 (3.93) 
Number of children, n; mean (standard deviation) n=361; 2.70 (1.97) n=272; 3.14 (2.18) 
Age at menarche, n; mean (standard deviation) n=334;13.58 (1.42) n=268; 13.83 (1.42) 
Premenopausal, n; % n=160; 43.10% n=151; 52.61% 
Postmenopausal, n; % n=212; 56.99% n=136; 47.39% 
Smoking status, n; % n=298; 27.85% n=275; 30.18% 
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Table 2.2. Selected Characteristics of Breast Cancer Patients and Age-matched Control Subjects in the Greek Population  
 
Characteristics   Cases Controls
Age, n; mean (standard deviation) n=92; 49.66 (14.87) n=176; 50.301 (12.83) 
Premenopausal, n; % n=92;  56% n=87;  46.8% 
Postmenopausal, n; % n=72;   44% n=99;  53.2% 
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2.1.2. Oligonucleotides 
Gene-specific DNA amplifications from genomic DNA were primed using 
oligonucleotide primers given in Table 2.3. 
 
 
Table 2.3. List of Primers Used for PCR Experiments 
 
Primer 
Name 
Sequence (5’ to 3’) Target 
Size of 
product (bp) 
Reference 
p21-F 
gtc aga acc ggc tgg gga tg 
 
p21-R ctc ctc cca act cat ccc gg 
p21 codon 31 
 
272 
Chen WC. 
et al. 2001 
Hsieh YY. 
et al. 2001 
p53-F tcc ccc ttg ccg tcc caa 
P53-R cgt gca agt cac aga ctt 
p53 codon 72 
 
279 
Storey  
et al. 1998 
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2.1.3. Chemicals and Reagents 
 
Agarose     Basica LE, EU 
Glacial Acetic Acid    Carlo Erba, Milano, Italy 
Bromophenol Blue    Sigma, St. Louis, MO, USA 
Chloroform     Carlo Erba, Milano, Italy 
Ethanol     Merck, Frankfurt, Germany 
Ethidium Bromide    Sigma, St. Louis, MO, USA 
Ficoll Type 400    Sigma, St. Louis, MO, USA 
Gamma Micropor Agarose   Prona LE, EU 
Isoamyl Alcohol    Carlo Erba, Milano, Italy 
Phenol      Merck, Darmstadt, Germany 
Proteinase K     Appligene-Oncor, USA 
pUC Mix Marker, 8 (0.5mg DNA/ml) MBI Fermentas Inc., NY, USA 
Sodium Acetate    Carlo Erba, Milano, Italy 
Sodium Dodecyl Sulfate(SDS)  Sigma, St. Louis, MO, USA 
TrisHCl     Sigma, St. Louis, MO, USA 
Xylene Cyanol    Sigma, St. Louis, MO, USA 
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2.1.4. PCR Materials 
All PCR materials were obtained from MBI Fermentas Inc., NY, USA. 
• Taq DNA Polymerase (5u/µl) 
• 10x PCR Buffer 
• 25 mM MgCl2  
• 10 mM dNTP mix 
 
2.1.5. Restriction Endonucleases 
Both restriction endonucleases were obtained from MBI Fermentas Inc., NY, USA. 
• Bpu 1102I (EspI), (10u/µl) 
Buffer Y+/Tango (10x), (1x buffer composition, 33mM Tris-acetate pH 7.9 at 
37 ˚C, 10mM magnesium acetate, 66mM potassium acetate, 0.1mg/ml BSA)  
• Bsh 1236I (Fnu DII), (10u/µl) 
Buffer R+(10mM Tris-HCl pH 8.5, 10mM magnesium chloride, 100 mM 
potassium chloride, 0.1 mg/ml BSA) 
 
2.1.6. Purification Kit 
NucleoSpin Extract 2 in 1 for direct purification of PCR products or DNA fragments 
from agarose gel was obtained from Macherey-Nagel. 
 
2.1.7. Sequencing Kit 
DYEnamic ET Terminator Cycle Sequencing Kit was used for sequencing reactions 
(Amersham Biosciences). The sequences were run on an ABI prism 377 automated 
sequencing machine. 
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2.1.8. Solutions 
• Agarose Gel Loading Buffer (6x) 
15 % ficoll 
0.05 % bromophenol blue 
 0.05 % xylene cyanol 
• DNA Extraction Buffer 
10 mM Tris HCl, pH 8.0 
10 mM EDTA, pH 8.0 
 0.5 % SDS 
• Ethidium Bromide 
10 mg/ml in water (stock solution), 30 ng/ml (working solution) 
• Proteinase K; 20 mg/ml (stock), 20 µg/ml (working solution)   
• SSC (20X), pH 7.0 
3 M NaCl 
            0.3 M Trisodium citrate 
• Tris Acetic Acid- EDTA Buffer (TAE) (50X) 
(1 liter), 242 gr Tris base 
57.1 ml glacial acetic acid  
37.2 gr EDTA 
• TE Buffer 
10 mM Tris-HCl pH 8.0  
1mM EDTA 
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2.1.9. Standard DNA Size Marker 
pUC Mix Marker, 8, (0.5 mg DNA/ml ), (MBI, Fermentas) 
1.7% Agarose, 0.5µg/lane, 8cm length gel, 1X TBE, 12V/cm 
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2.2. METHODS 
 
2.2.1. DNA Isolation From Human Blood 
Peripheral blood was collected into EDTA containing tubes and stored at 4˚C. Blood 
samples can be stored at 4˚C for a maximum of five days before being aliquoted and 
frozen. Before DNA isolation, the blood samples were frozen at –40˚C  in 800 µl 
aliquots. The samples were thawed as required and 800 µl of 1x SSC was added and 
mixed by vortexing. Centrifugation at 13,000 rpm was carried out for one minute. 
The supernatant was removed and discarded into disinfectant. It is important not to 
disturb the cell pellet during this procedure. 1.4 ml of 1x SSC was added over the 
pellet, vortexed briefly, and centrifuged for one minute at 13,000 rpm. All the 
supernatant was removed carefully. The washing step was repeated until the pellet 
became sufficiently clear. 800 µl of DNA extraction buffer and 20 µl of proteinase K 
(20 mg/ml) were added. After brief vortexing the samples were incubated at 56˚C 
overnight. Once the cell pellet was dissolved completely, 400 µl of phenol/ 
chloroform/ isoamyl alcohol (25:24:1) was added and the samples were vortexed for 
60 seconds. This step must be carried out under a fume hood.  Centrifugation for five 
minutes was carried out at 13,000 rpm. The upper DNA-containing aqueous layer (~ 
700 µl) was collected into a new tube. The extraction step can be repeated by adding 
350 µl of phenol/ chloroform/ isoamyl alcohol if the DNA supernatant is sticky 
and/or if the interface is not clear enough. Then 35 µl of NaOAc (3M, pH 5.2) and 
700 µl of cold absolute ethanol (EtOH) were added. The tubes were mixed by 
inversion and placed at –20˚C for 30 minutes or more (maximum overnight). After 
centrifugation for five minutes at 13,000 rpm, EtOH was removed with a 
micropipette and the tubes were left open for air-dry of ethanol. The DNA pellet was 
dissolved  in 200 µl of TE (pH 8.0) or in sterile ddH20 by incubating at 56˚C for a 
minimum of 1 hour. Incubation can be performed overnight at 56˚C if it is necessary 
to dissolve the pellet. The DNA samples were stored at 4˚C or at -20˚C for a long 
term. 
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2.2.2. Polymerase Chain Reaction (PCR) 
The polymerase chain reaction is a DNA amplification method. The DNA template is 
amplified enzymatically in the presence of sequence-specific single-stranded DNA 
oligonucleotide primers (forward and reverse), four deoxyribonucleoside 
triphosphates (dATP, dGTP, dCTP, dTTP), and DNA Taq polymerase. 
All PCR amplifications were carried out on Gene Amp PCR System Perkin Elmer 
(9600) or Techne (Techgene) PCR machines. 
 
2.2.3. Restriction Endonuclease Digestion 
Restriction endonuclease digestions were performed in order to analyze the S31R 
polymorphism in p21 and the R72P polymorphism in p53 genes. The enzyme 
digestion reactions were carried out in 25 µl reaction volume containing 20 µl of 
PCR product (diluted if necessary), 10 x buffer Y+/Tango for p21 digestion and R+ 
buffer for p53 digestion, 2.5 units of Bpu 1102I for p21 digestion and Bsh 1236I for 
p53 digestion. The samples were incubated at 37˚C for four hours. 
 
2.2.4. Agarose Gel Electrophoresis 
Agarose gel electrophoresis was performed in order to analyze PCR products and 
restriction fragments. pUC Mix8 was used as the DNA size marker. 
PCR products were run on 2% (w/v) agarose gel. 1x TAE buffer was used to prepare 
the gel and ethidium bromide solution was added (stock: 10mg/ml, final: 30 ng/ml). 
5 µl of PCR product was mixed with 1µl 6x loading buffer and the mixture was 
loaded into the wells of the gel. The products were run at 100 V for 20 minutes. The 
gel was then visualized under the UV transilluminator and photographs were taken. 
The restriction fragments were run on 3% (w/v) Agarose: Gamma Micropor (1:1) 
gel. 20 µl of digested product and 4 µl of 6x loading buffer containing mix was 
prepared and then loaded onto the gel. Running procedure was carried out at 80v for 
45- 60 minutes. The gel was visualized under UV light and photographs were taken. 
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2.2.5. Genotyping of Subjects 
The p21 codon 31 and p53 codon 72 polymorphisms were both analyzed by PCR- 
based restriction endonuclease enzyme digestion. Genotyping was performed by 
visualizing the restriction fragments under the UV light. 
 
2.2.5.1. p21 Codon 31 Genotyping 
The p21 codon 31 polymorphism results from a single base change in codon 31 from 
AGC to AGA and an amino acid change from serine to arginine. Bpu1102I  has a 
restriction recognition site (5`…GC↓TNAGC…3`) at codon 31 when it is AGC 
(serine) and the change to AGA (arginine) diminishes this site leading to uncut 
fragments.  
Most of the samples were subjected to PCR to a total volume of  25 µl, containing 
genomic DNA, 10 pmol of each primer, 1x PCR buffer (- MgCl2), 1.5 mM MgCl2, 
200 µM dNTP mix, and  1U Taq DNA polymerase. For the samples which did not 
yield enough product with the above concentrations some alternative combinations 
were used. Increasing the primer concentrations to 12.5 pmol and/or MgCl2 
concentration to 2 or 4 mM gave better results for these samples. The cycling 
conditions were as follows: one cycle (denaturing) at 94˚C for 5 min, 35 cycles at 
94˚C (denaturing) for 30s, 60˚C (annealing) for 40 s, 72˚C (extension) for 40s, and a 
final extension cycle at 72˚C for 7 min. The expected amplification product was 272 
bp. After digestion with 2.5 U Bpu1102I for 3.5 hrs at 37˚C, the cut product gave 89 
and 183 bp bands on gel indicating the serine allele, whereas the uncut product gave 
only a 272 bp band indicating the arginine allele. The products with heterozygous 
nature gave three bands: 89, 183, and 272 bp. The figure 2.1 shows the schematic 
representation of the expected digestion patterns. 
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2.2.5.2. p53 Codon 72 Genotyping 
The p53 codon 72 polymorphism results from a single base change in codon 72 from 
CGC to CCC and an amino acid change from arginine to proline. Bsh1236I  has a 
restriction recognition site (5`…CG↓CG…3`) at codon 72 when it is CGC (arginine) 
and the change to CCC (proline) diminishes this site leading to uncut fragments.  
Most of the samples were subjected to PCR to a total volume of  25 µl, containing 
genomic DNA, 10 pmol of each primer, 1x PCR buffer (- MgCl2), 1.5 mM MgCl2, 
200 µM dNTP mix, and  1U Taq DNA polymerase. The cycling conditions were as 
follows: one cycle (denaturing) at 94˚C for 5 min, 35 cycles at 94˚C (denaturing) for 
30s, 60˚C (annealing) for 30s, 72˚C (extension) for 30s, and a final extension cycle at 
72˚ C for 7 min. The expected amplification product was 279 bp. After digestion 
with 2.5 U Bsh1236I for 3.5 hrs at 37˚C, the cut product gave 119 and 160 bp bands 
on gel indicating the arginine allele, whereas the uncut product gave only 279 bp 
band indicating the proline allele. The products having both alleles gave three bands: 
119, 160, and 279 bp. The figure 2.2 shows the schematic representations of the 
expected digestion patterns. 
 
2.2.5.3. Sequencing 
PCR products were used as templates for sequencing reactions after purification with 
NucleoSpin Extract 2 in 1. The reactions were carried out with forward and reverse 
primers for the specific DNA sequence, DYEnamic ET Terminator Cycle 
Sequencing Kit (Amersham Biosciences), and the reactions were run on the ABI 
PRISM 377 DNA Sequencer machine. 
The sequenced samples for both p21 and p53 were used as controls in every 
digestion reaction.   
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Figure 2.1. Schematic Representation of Genotyping of p21 Codon 31 Polymorphism. Pattern 1,2 and 3 show the Bpu1102I restriction enzyme 
digestion profile.   
 
 
Size 
PCR 
product 
Pattern 1 Pattern 2 Pattern 3 
 
 
272 bp 
 
183 bp 
 
 
89 bp 
    
 
 
 
 
 
uncut Arg/ Arg Ser/ Arg Ser/ Ser 
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Figure 2.2. Schematic Representation of Genotyping of p53 Codon 72 Polymorphism. Pattern 1,2 and 3 show the Bsh1236 restriction enzyme 
digestion profile.   
 
Size 
PCR 
product 
Pattern 1 Pattern 2 Pattern 3 
 
 
279 bp 
 
 
160 bp 
 
 
 
119 bp 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
uncut Pro/ Pro Arg/ Pro Arg/ Arg 
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2.2.6. Statistical Analyses  
The Minitab 13.1 software program was used for statistical analysis of the data. 
Binary logistic regression analysis was performed for odds ratio and confidence 
interval calculations. Adjusted odds ratio calculations were carried out with the 
SPSS software program. 
 
2.2.6.1. Hypothesis Testing 
A hypothesis is a statement about one or more populations (Daniel 1995). The 
purpose of hypothesis testing is to aid the clinician, researcher, or administrator 
in reaching a conclusion concerning a population by examining a sample from 
that population. Hypothesis testing is carried out on two statistical hypotheses 
that should be stated separately. The null hypothesis (H0) is the hypothesis to be 
tested, while the alternative hypothesis (HA) is a statement of what we will 
believe is true if our sample data causes us to reject the null hypothesis. The null 
hypothesis is sometimes referred to as a hypothesis of no difference, since it is a 
statement of agreement with (or no difference from) conditions presumed to be 
true in the population of interest. Usually the alternative hypothesis and the 
research hypothesis are the same, and the two terms may be used in an  
interchangeable manner. For example, in this study, we have tried to investigate 
whether the cases and the controls can be accepted as statistically different 
populations based on p53 codon 72 Arg/Arg genotype frequency. While the  
alternative hypothesis would be the statement that the cases and the controls are 
different populations based on p53 codon 72 Arg/Arg genotype frequency, the 
null hypothesis would be the opposite statement of the alternative hypothesis. If it 
is possible to reject H0 after statistical analyses, the research hypothesis would be 
accepted. 
The decision as to which values go into the rejection region and which ones go 
into the non-rejection region is made on the basis of the desired level of 
significance (α). The level of significance is the probability of rejecting a true 
null hypothesis. Because rejecting a true null hypothesis would constitute an 
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error,  a small value of α should be selected. The more frequently selected values 
of α are 0.01, 0.05, and 0.10. In our study we selected α value of 0.05. 
 
2.2.6.1.1. Types of Errors 
The error committed when a true null hypothesis is rejected is called a type I 
error. A type II error is the error committed when a false null hypothesis is not 
rejected. The probability of committing a type II error is designated by β. Table 
2.4 summarizes conditions under which type I and type II errors are committed 
(Daniel 1995).   
 
Table 2.4. Conditions under which Type I and II Errors may be Committed 
 
 CONDITION OF NULL HYPOTHESIS 
 True False 
Fail to reject H0 Correct action Type II error 
POSSIBLE 
ACTION 
Reject H0 Type I error Correct action 
    
 
2.2.6.1.2. P-Values 
The p value for a hypothesis test is the probability of obtaining, when H0 is true, 
a value of the test statistic as extreme as or more extreme (in the appropriate 
direction) than the one actually computed. The quantity p is referred to as the p 
value for the test (Daniel 1995). 
The p value for a test may be defined also as the smallest value of α for which 
the null hypothesis can be rejected. If the p value is less than or equal to α, the 
null hypothesis is rejected. If the p value is greater than α, the null hypothesis is 
not rejected.  
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2.2.6.1.3. Confidence Interval 
100(1-α)% confidence interval (CI) calculation is another method usually used 
for usual probabilistic and practical interpretations. It is calculated from the  
standard deviation and sample size values and gives us 100(1-α) percent 
confidence that the calculated parameter (i.e. odds ratio, mean) is contained in the 
calculated confidence interval. It is possible to conclude this because in repeated 
sampling, 100(1-α) percent of the intervals that may be constructed in this 
manner will include the true parameter. We used 95% CI (if α= 0.05, 100(1-α)% 
=95%) for odds ratio calculation. For the calculated odds ratio we can say that in 
repeated data sets, 95% of the cases will have an odds ratio value within the 
calculated interval but the other 5% will not.   
 
2.2.6.2. The Chi-Square Distribution Test 
The chi-square is the most frequently employed statistical technique for the 
analysis of count or frequency data. The hypothesis testing procedures that use 
the chi-square distribution are the tests of goodness-of-fit, tests of independence, 
and tests of homogeneity. 
The most frequent use of the chi-square distribution is to test the null hypothesis 
that the two criteria of classification, when applied to the same set of entities, are 
independent. 
The characteristics of a chi-square test of independence that distinguish it from 
other chi-square tests are as follows (Daniel 1995): 
1. A single sample is selected from a population of interest and the subjects 
or objects are cross-classified on the basis of the two variables of interest. 
2. The rationale for calculating expected cell frequencies is based on the 
probability law, which states that if two events (the two criteria of 
classification) are independent, the probability of their joint occurence is 
equal to the product of their individual probabilities. 
3. The hypotheses and conclusions are stated in terms of the independence 
(or lack of independence) of two variables. 
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In this study, the chi-square distribution was used to test whether there is a 
relationship between p21 codon 31 and/or p53 codon 72 genotypes and the risk 
of developing breast cancer among subjects and the control groups. 
The classification, according to two criteria, of a set of entities can be shown by a 
table in which r rows represent the various levels of one criterion of classification 
and the c columns represent the various levels of the second criterion. Such a 
table is called a contingency table. The computed value of X2 is compared with 
the tabulated value of X2 with k – r degrees of freedom, where k is equal to the 
number of groups for which observed and expected frequencies are available, and 
r is the number of restrictions and constraints imposed on the given comparison.  
X2 is distributed approximately with (r-1)(c-1) degrees of freedom when the null 
hypothesis is true. If the computed value of X2 is equal to or larger than the 
tabulated value of X2 for some α, the null hypothesis is rejected at the α level of 
significance (Daniel 1995).  
Sometimes each of two criteria of classification may be broken down into only 
two categories, or levels. When data are cross-classified in this manner, the result 
is a contingency table consisting of two rows and two columns. Such a table is 
commonly referred as a 2 X 2 table. The value of X2 may be calculated by the 
following formula: 
 
X2 = ( )( )( )( )( )dcbadbca
bcadn
++++
− 2  
 
Where a, b, c, and d are the observed cell frequencies as shown in Table 2.5. 
When the (r-1)(c-1) rule is applied for finding degrees of freedom to a 2 X 2 
table, the result is 1 degree of freedom.  
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 Table 2.5. A 2 X 2 Contingency Table (Daniel 1995) 
First criterion of classification Second criterion 
of classification 1 2 Total 
1 a b a+b 
2 c d c+d 
Total a+c b+d N 
 
 
The problems of how to handle small expected frequencies and small total sample 
sizes  may arise in the analysis of 2 X 2 contingency tables. It is suggested that X2 
test should not be used if n < 20 or if 20 < n < 40 and any expected frequency is less 
than 5. When n ≥ 40 an expected cell frequency as small as 1 can be tolerated. 
 
2.2.6.3 Relative Risk and Odds Ratio Calculation 
An observational study is a scientific investigation in which neither the subjects 
under study nor any of the variables of interest are manipulated in any way. 
The term risk factor is used to designate a variable that is thought to be related to 
some outcome variable. The risk factor may be a suspected cause of some specific 
state of the outcome variable (Daniel W.W. 1995). 
In a particular investigation, for example, the outcome variable might be the 
subjects’ status relative to cancer and the risk factor might be their status with respect 
to cigarette smoking. The model is further simplified if the variables are categorical 
with only two categories per variable. For the outcome variable the categories might 
be ‘cancer present’ and ‘cancer absent’. With respect to the risk factor the subjects 
might be categorized as smokers and nonsmokers. 
There are two basic types of observational studies, prospective and retrospective  
(Daniel 1995).  
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A prospective study is an observational study in which two random samples of 
subjects are selected: One sample consists of subjects possessing the risk factor and 
the other sample consists of subjects who do not possess the risk factor. The subjects 
are followed into the future (that is, they are followed prospectively) and a record is 
kept on the number of subjects in each sample who, at some point in time, are 
classifiable into each of the categories of the outcome variable. For example, if our 
case were a prospective study, we would collect random samples of subjects, then 
perform p53 codon 72 genotyping experiments, categorize the samples into two 
groups depending on the genotype, and then follow-up the subjects for 30 years to 
observe which group will develop breast cancer with greater frequency. 
   
A retrospective study is the reverse of a prospective study and is the way that our 
study was conducted. The samples are selected from those falling into the categories 
of the outcome variable (breast cancer patients and subjects with no history of breast 
cancer). The investigator then looks back (that is, takes a retrospective look) at the 
subjects and determines which ones have (or had) and which ones do not have (or did 
not have) the risk factor (e.g. p53 codon 72 Arg/Arg genotype). 
 
Relative risk is the ratio of the risk of developing a disease among subjects with the 
risk factor to the risk of developing the disease among subjects without the risk 
factor. A retrospective study is based on a sample of subjects with the disease (cases) 
and a separate sample of subjects without the disease (controls or noncases). The 
distribution of the risk factor among the cases and controls is determined 
retrospectively. Given the results of a retrospective study involving two samples of 
subjects, cases and controls, the data may be displayed in a 2 X 2 table such as Table 
2.5, in which subjects are dichotomized with respect to the presence and absence of 
the risk factor. 
  
Odds ratio calculation: The appropriate measure for comparing cases and controls 
in a retrospective study is the odds ratio (Daniel 1995). Using probability 
terminology odds is defined as follows: The odds for success is the ratio of the 
probability of success to the probability of failure. 
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Table 2.6. Subjects of a Retrospective Study Classified According to Status Relative 
to Risk Factor and Whether They Are Cases or Controls. 
 
Sample 
Risk Factor Cases Controls Total 
Present a b a+b 
Absent c d c+d 
Total a+c b+d n 
 
The definition of odds is used to define two odds that can be calculated from the data 
displayed as in Table 2.6. 
1. The odds of being a case (having the disease) to being a control (not having 
the disease) among subjects with the risk factor is [a/(a+b)]/ [b/(a+b)] = a/b. 
2. The odds of being a case (having the disease) to being a control (not having 
the disease) among subjects without the risk factor is [c/(c+d)]/ [d/(c+d)] = 
c/d. 
The odds ratio is computed from the data of a retrospective study. The symbol OR is 
used to indicate that the measure is computed from sample data and used as an 
estimate of the population odds ratio, OR (Daniel 1995).  
The estimate of the population odds ratio is: 
 
OR = 
dc
ba
/
/ = 
bc
ad  
 
95% CI= eln(OR)± 1.96 times square root of (1/a+1/b+1/c+1/d)  
 
where a, b, c, and d are defined in Table 2.6. 
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The odds ratio can assume values between zero and ∞. A value of zero indicates no 
association between the risk factor and the disease status. A value less than 1 
indicates reduced odds of the disease among subjects with the risk factor. A value 
greater than 1 indicates increased odds of having the disease among subjects in 
whom the risk factor is present. 
Before calculating the odds ratios and the 95% confidence intervals with Minitab 
13.1 software program, the tables for risk and non-risk groups were prepared. While 
the variables in the risk-groups (i.e. being Arg/Arg at p53 codon 72) were coded as 
‘1’, non-risk variables were coded as ‘0’. Similarly, breast cancer subjects were 
coded as ‘1’, meaning that they possess a response under the risk and the control 
subjects were coded as ‘0’ for the response variable. Appendix  shows the coding of 
every table in the results part. 
 
2.2.6.4. Allele Frequency Calculation 
p= [2(number of homozygotes)+ (number of heterozygotes)]/total number of samples  
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3. RESULTS  
 
Associations between p53 codon 72 and p21 codon 31 polymorphisms and breast 
cancer risk in the Turkish and Greek populations were studied. 
 
3.1. Genotyping  
 
Genotyping of both p53 codon 72 and p21 codon 31 was performed by polymerase 
chain reaction (PCR) followed by restriction endonuclease digestion. 
 
3.1.1. Genotyping of p53 codon 72 
The number of subjects genotyped for p53 codon 72 was 274 breast cancer patients 
and 221 controls. 132 of the cases and 88 of the controls were Arg/Arg, 126 of the 
cases and 110 of the controls were Arg/Pro, and 16 of the cases and 23 of the 
controls were Pro/Pro at codon 72 (Table 3.2). 
Polymerase chain reaction for p53 gives a product of 279 bp. An example of the PCR 
results of p53 product is shown in Figure 3.1. At codon 72, the CGC encodes the 
Arg allele and has a Bsh1236I restriction enzyme site, while CCC encodes the Pro 
allele and does not have the restriction enzyme site. Therefore, the Bsh1236I 
endonuclease digestion of 279 bp PCR product gives three different band patterns as 
expected. A single band of 279 bp is observed when a sample is Pro/Pro, two bands 
of 160 bp and 119 bp are observed for the Arg/Arg genotype, and three bands of 279, 
160, and 119 bp are observed in the case of heterozygous samples. Figure 3.2 shows 
an example for the Bsh1236I enzyme digestion pattern of  279 bp PCR product of 
p53 region. 
Some of the samples were sequenced in order to control the results of the digestion 
reactions. After confirming the digestion results, these samples were used as controls 
for every digestion reaction. Figure 3.3 A shows the agarose gel photograph of the 
Bsh1236I enzyme digestion pattern of p53 PCR products. Lanes 4, 7 and 9 are 
samples MCK13, MCK32 and MCK18, respectively. Figure 3.3 B shows the 
sequencing reaction results of the p53 PCR products of the samples MCK13, 
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MCK32 and MCK18, which were used as control DNAs for the subsequent 
restriction enzyme digestion experiments. Primers p53-F and p53-R were used as 
sequencing primers. These results show that the sample MCK13 is homozygote for 
Pro allele, MCK32 is homozygote for Arg allele and MCK18 is heterozygote and 
carries both Arg and Pro alleles.  
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Figure 3.1.  Agarose gel photograph of PCR products for p53 region: primers p53-F and p53-R give 279 bp PCR product. M; DNA size marker 
(pUC mix 8), lane1; negative control, lanes 2-24 are the samples YB266, YB267, YB270, YB271, YB273-YB289, YB291, and YB292 
respectively. The PCR reactions did not result with a product for the samples in lanes 11, 13 and 18.  
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 279 bp 
          160 bp 
          119 bp 
               M      1        2       3       4       5       6       7       8       9      10     11     12      13     14    15     16      17     18     19     20     21  
 
 
Figure 3.2. Genotyping of the p53 gene at codon 72. M; DNA size marker (pUC mix 8).  279 bp PCR products were digested with Bsh1236I. A 
single band of 279 bp was observed when the sample is Pro/Pro; lanes 1(MCK 13), 5 (MFN4), 16 (MFN 26). Two bands of 160 bp and 119 bp 
were observed for the Arg/Arg genotype; lanes 3, 6, 8, 11, 13, 17, 18, 19, 21 (MCK 22, MFN5, -13, -17, -22, -27, -28, -29, and -34). Three bands 
of 279, 160, and 119 bp were observed in the case of heterozygous samples; lanes 2, 4, 7, 9, 10, 12, 14, 15, 20 (MCK19, GK100, MFN12, -14, -
16, -18, -23, -25, and -33).   
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Figure 3.3. Restriction enzyme digestion and sequencing reaction results for p53 samples. A) Agarose gel photograph of Bsh1236I enzyme 
digested samples for p53 codon 72. M; DNA size marker. The sample (MCK13) at lane 4 was homozygous for Pro allele, the sample (MCK32) 
at lane 7 was homozygous for the Arg allele, and the sample at lane 9 (MCK18) was heterozygous at codon 72. B) The PCR products of the 
samples in lanes 4, 7 and 9 were used for the sequencing reactions. The genotyping results with the digestion patterns were confirmed with the 
sequencing reactions. Lane 4: CCC (homozygous for Pro allele), lane 7: CGC (homozygous for Arg allele), lane 9: CCC or CGC (heterozygous; 
contains both Arg and Pro alleles).   
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3.1.2. Genotyping of p21 codon 31 
The number of subjects genotyped for p21 codon 31 was 322 breast cancer patients 
and 246 controls. 259 of the cases and 203 of the controls were Ser/Ser, 59 of the 
cases and 41 of the controls were Ser/Arg, and 4 of the cases and 2 of the controls 
were Arg/Arg at codon 31. 
Polymerase chain reaction for p21 gives a product of 272 bp. An example of the PCR 
results of p21 product is shown in Figure 3.4. At codon 31, the AGA encodes the Arg 
allele and does not have a restriction site for Bpu1102I enzyme, while AGC encodes 
the Ser allele and has a restriction site for the enzyme. Therefore, the restriction 
endonuclease digestion of 272 bp PCR product gives three different band patterns as 
expected. A single band of 272 bp is observed when a sample is Arg/Arg, two bands 
of 183 and 89 bp are observed for the Ser/Ser genotype, and three bands of 272, 183, 
and 89 bp are observed in the case of heterozygous samples. Figure 3.5 shows an 
example for the Bpu1102I enzyme digestion pattern of 272 bp PCR product of p21 
region. 
Some of the samples were sequenced in order to control the results of the digestion 
reactions. After confirming the digestion results, these samples were used as controls 
for every digestion reaction. Figure 3.6 A shows the agarose gel photograph of the 
Bpu1102I enzyme digestion patterns of p21 PCR products. Lanes 3, 4 and 6 are 
samples MCK68, MFN21 and MFN45, respectively. 
Figure 3.6 B shows the sequencing reaction results of the p21 PCR products of the 
samples in lanes 3, 4 and 6 which were used as control DNAs for the subsequent 
restriction enzyme digestion experiments. Primers p21-F and p21-R were used as 
sequencing primers. These results show that the sample MCK68 is homozygous for 
Arg allele, MFN21 is homozygous for Ser allele and MFN45 is heterozygous and 
carries both Arg and Ser alleles. 
 
All the breast cancer patient and control DNA samples were subjected to the 
restriction enzyme analysis for genotyping. The results were used for statistical 
analyses to evaluate the p53 codon 72 and p21 codon 31 genotypes and their 
association with various risk factors for breast cancer susceptibility. 
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Figure 3.4.  Agarose gel photograph of PCR products for p21 region: primers p21-F and p21-R give 272 bp PCR product. M; DNA size marker 
(pUC mix 8), lane1; negative control, lanes 2-24 are the samples YB252-262, YB266, YB267, YB270, YB271,YB273-279 respectively. The 
PCR reactions did not result with a product for the sample in lane 22.  
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Figure 3.5.  Genotyping of the p21 gene at codon 31. M; DNA size marker (pUC mix 8).  272 bp PCR products were digested with Bpu1102I. A 
single band of 272 bp was observed when the sample is Arg/Arg, lanes 1(MCK 68). Two bands of 183 bp and 89 bp were observed for the 
Ser/Ser genotype; lanes 2, 4-20 (MFN 21, AB1-5, AB8-19). Three bands of 272, 183, and 89 bp were observed in the case of heterozygous 
samples; lanes 3 and 21 (MFN45 and AB20).   
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Figure 3.6.  Restriction enzyme digestion and sequencing reaction results for p21 samples. A) Agarose gel photograph of Bpu1102I  enzyme 
digested samples for p21 codon 31. M; DNA size marker. The sample (MCK68) at lane 3 was homozygous for the Arg allele, the sample 
(MFN21) at lane 4 was homozygous for the Ser allele, and the sample at lane 6 (MFN45) was heterozygous at codon 31. B) The PCR products of 
the samples in lanes 3, 4 and 6 were used for sequencing reaction. The genotyping results with the digestion patterns were confirmed with the 
sequencing reaction. Lane 3: AGA (homozygous for Arg allele), lane 4: AGC (homozygous for Ser allele), lane 6: AGA or AGC (heterozygous; 
contains both Arg and Ser alleles). 
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3.2. Statistical Analysis  
3.2.1. Characteristics of the Subjects in the Turkish  Population 
The genotyping results of breast cancer patients and controls were subjected to 
statistical analyses. The statistical analyses was performed by using the Minitab and 
SPSS software programs. Table 3.1 summarizes the general characteristics of the 
subjects in the Turkish population. Results were analyzed whenever information for 
subjects was available. For the group of cases, the mean age was 49.30 (SD: 12.45, 
range: 20-80), the mean age at menarche was 13.58 (SD: 1.42, range: 11-20), the 
mean age at first live birth was 22.51 (SD: 5.14, range: 15-42), the mean number of 
children was 2.70 (SD: 1.99, range: 0-12), and the mean BMI (kg/m2) was 27.27 
(SD: 4.95, range: 16.02-42.22). For the control group, the mean age was 46.59 (SD: 
14.42, range: 15-83), the mean age at menarche was 13.83 (SD: 1.42, range: 10-19), 
the mean age at first live birth was 20.56 (SD: 3.93, range: 14-37), the mean number 
of children was 3.14 (SD: 2.18, range: 0-12), and the mean BMI (kg/m2) was 27.40 
(SD: 5.26, range: 14.69-44.06). When the subjects were grouped according to their 
menopausal status, 43.10% of the cases and 52.61% of the controls were 
premenopausal, while 56.99% of the cases and 47.39% of the controls were 
postmenopausal. The higher frequency of postmenopausal cases compared to 
postmenopausal controls resulted in a higher risk of breast cancer for women who 
were postmenopausal (OR= 1.47, 95% CI= 1.08-2.00).  
We examined whether the age at menarche being greater than 14 is a risk factor for 
breast cancer. 54.19% of the cases and 43.28% of controls were in this group and this 
gives us a significant association between age at menarche greater than 14 and breast 
cancer risk (OR=1.55, 95% CI=1.12-2.14).  
Another parameter that we examined for breast cancer risk association was the BMI. 
Having a BMI greater than the mean BMI of the control group (27.40) was 
considered to be a risk factor, but no significant results were obtained (OR=0.90, 
95% CI=0.65-1.24).  
When we analyzed the subjects according to their smoking status, we again could not 
find any significant association between smoking status and breast cancer risk 
(OR=0.89, 95% CI=0.62-1.28).  
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While the frequency of cases with a family history of breast cancer was 14.48%, the 
frequency for the control group was only 2.46%. OR calculation from these 
frequencies show that women with a family history of breast cancer have 6.72 times 
higher risk for the development of breast cancer compared to women without a 
family history of breast cancer (OR=6.72, 95% CI= 2.97-22) (Table 3.1). 
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Table 3.1. General Characteristics of the Subjects in the Turkish Study Population 
 
 
 Characteristics Cases Controls 
(n; mean or %) (n; mean or %) 
OR (95%CI) 
Age n=370; 49.30 n=288; 46.59  
Family history of breast cancer n=297; 14.48% n=285; 2.46% 6.72 (2.97-15.22) 
Body mass index (BMI) n=331; 27.267 n=274; 27.399  
BMI≥27.40 n=331; 44.71% n=274; 47.45% 0.90 (0.65-1.24) 
Age at first live birth n=318; 22.51 n=244; 20.56  
Number of children n=361; 2.70 n=272; 3.14  
Age at menarche n=334;13.58   n=268; 13.83
Age at menarche<14 n=334; 54.19% n=268; 43.28% 1.55 (1.12-2.14) 
Premenopausal n=160; 43.10% n=151; 52.61% 0.68 (0.50-0.93) 
Postmenopausal n=212; 56.99% n=136; 47.39% 1.47 (1.08-2.00) 
Smoking n=298; 27.85% n=275; 30.18% 0.89 (0.62-1.28) 
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3.2.2. Genotype Distributions in the Turkish Population 
p53 codon 72 and p21 codon 31 genotype distributions in the case and control groups 
were examined and OR calculations were carried out in order to determine the 
genotypes of the risk groups and the degree of association between the risk groups 
and breast cancer incidence. ORs were adjusted according to menopausal status, age, 
smoking status, body-mass-index (BMI), age at menarche, age at first live birth, 
number of children, and family history of breast cancer. Genotype distributions were 
also classified according to menopausal status and BMI. The results are summarized 
in Tables 3.2, 3.3, and 3.4. 
 
3.2.2.1. Distribution of the p53 Codon 72 Genotype 
Table 3.2 shows the distribution of the p53 codon 72 genotypes in the age-matched 
controls and breast cancer patients. The p53 codon 72 Arg/Arg genotype was 
determined to be a risk factor for breast cancer with a crude odds ratio of 2.16 (95% 
CI=1.08-4.31) for all subjects. The crude odds ratios for other genotypes were 1.65 
(95% CI 0.83-3.27) for the Arg/Pro genotype, 0.46 (95% CI=0.23-0.93) for the 
Pro/Pro genotype (serves as the reference group), and 0.71 (95% CI=0.50-1.02) for 
the combined Pro/Pro and Arg/Pro genotypes. The crude odds ratios for 
premenapousal women were 2.59 (95% CI=0.97-6.93) for the Arg/Arg genotype, 
2.30 (95% CI=0.87-6.09) for the Arg/Pro genotype, 0.39 (95% CI=0.14-1.03) for the 
Pro/Pro genotype, and 0.78 (95% CI=0.46-1.32) for the combination of Pro/Pro and 
Arg/Pro genotypes. The crude odds ratios for postmenopausal women were 1.37 
(95% CI=0.48-3.95) for the Arg/Arg genotype, 1.02 (95% CI=0.36-2.91) for the 
Arg/Pro genotype, 0.73 (95% CI=0.25-2.09) for the Pro/Pro genotype, and 0.74 
(95% CI=0.45-1.22) for the combination of Pro/Pro and Arg/Pro genotypes. 
The adjusted odds ratios were 1.62 (95% CI=0.60-4.35) for the Arg/Pro genotype 
and 1.88 (95% CI=0.69-5.10) for the Arg/Arg genotype when both premenopausal 
and postmenopausal subjects were considered. We observed an important decrease in 
OR for the risk group Arg/Arg genotype. When subjects were classified according to 
their menopausal status, the menopausal status was excluded for the adjusted OR 
calculation. In the premenopausal group, the adjusted odds ratios were 2.26 (95% 
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CI=0.53-9.61) for the Arg/Pro genotype and 2.60 (95% CI=0.59-11.38) for the 
Arg/Arg genotype. In the postmenopausal group, the adjusted odds ratios were 1.27 
(95% CI=0.23-6.87) for the Arg/Pro genotype and 1.57 (95% CI=0.29-8.62) for the  
Arg/Arg genotype. 
 
3.2.2.2. Distribution of p53 Genotypes According to BMI  
Table 3.3 shows the analysis of the p53 codon 72 genotypes stratified according to 
BMI based on the median value for controls. Two main groups of analysis are the 
subjects with BMI value below 27.40 and the subjects with BMI value equal to or 
above 27.40. Among the subjects with high BMI (≥27.40), the Arg/Arg genotype had 
a significantly increased risk for breast cancer (OR=3.86, 95% CI=1.12-13.26). The 
odds ratios for pre- or postmenopausal status had not shown significant increase for 
Arg/Arg or the combination of Arg/Arg and Arg/Pro genotypes.  
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Table 3.2. Distribution of the p53 Codon 72 Genotypes Stratified According to Menopausal Status in the Age-matched Control and Breast 
Cancer Patients. 
Menopausal status Genotype Case  (%), n=274 Control  (%), n =221 Crude OR  95% CI Adjusted ORa 95% CI 
All R/R 132 (48.18) 88 (39.82) 2.16 (1.08-4.31) 1.88 (0.69-5.10) 
 R/P 126 (45.99) 110 (49.77)   1.65 (0.83-3.27) 1.62 (0.60-4.35)
 P/P 16 (5.84) 23 (10.41)  0.46 (0.23-0.93) 1.00b 
 R/P+P/P 142  (51.82) 133 (60.18)   0.71 (0.50-1.02)
Menopausal status Genotype Case  (%), n=116 Control  (%), n=111 Crude OR  95% CI Adjusted OR 95c% CI 
Pre       R/R 52 (44.83) 43 (38.74) 2.59 (0.97-6.93) 2.60 (0.59-11.38)
 R/P 57 (49.14) 53 (47.75)   2.30 (0.87-6.09) 2.26 (0.53-9.61)
 P/P 7 (6.03) 15 (13.51)  0.39 (0.14-1.03) 1.00b 
 R/P+P/P 64 (55.17) 68 (61.26)   0.78 (0.46-1.32)
Menopausal status Genotype Case  (%), n=153 Control  (%), n=102 Crude OR  95% CI Adjusted OR 95c% CI 
Post       R/R 76 (49.67) 43 (42.16) 1.37 (0.48-3.95) 1.57 (0.29-8.62)
 R/P 68 (44.44) 52 (50.98)   1.02 (0.36-2.91) 1.27 (0.23-6.87)
 P/P 9 (5.88) 7 (6.86)  0.73 (0.25-2.09) 1.00b 
 R/P+P/P 77 (50.33) 59 (57.84)   0.74 (0.45-1.22)
 
a) Adjustment is according to menopausal status, age, age at menarche, age at full-term pregnancy, number of children, family history of breast cancer,  and smoking. 
b) Reference group 
c) Adjustment is according to age, age at menarche, age at full-term pregnancy, number of children, family history of breast cancer,  and smoking. 
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Table 3.3. Distribution of the p53 Codon 72 Genotypes Stratified According to BMI in Cases and Controls. 
 
Low BMI (<27.40) High BMI (≥27.40) 
Menopausal 
status 
Genotype Cases; n (%) 
n=131 
Controls; n (%) 
n=108 
OR (95% CI) Cases; n (%) 
n=107 
Controls; n (%) 
n=97 
OR (95% CI) 
All P/P 10 (7.63) 12 (11.11)  4 (3.74) 10 (10.31)  
 R/R 57 (43.51) 47 (43.52) 1.46 (0.58-3.67) 54 (50.47) 35 (36.08) 3.86 (1.12-13.26) 
 R/P+R/R 121 (92.37) 96 (88.89) 1.51 (0.63-3.65) 103 (96.26) 87 (89.69) 2.96 (0.90-9.77) 
Menopausal 
status 
Genotype Cases; n (%) 
n=65 
Controls; n (%) 
n=70 
OR (95% CI) Cases; n (%) 
n=37 
Controls; n (%) 
n=38 
OR (95% CI) 
Pre P/P 5 (7.69) 9 (12.86)  2 (5.41) 6 (15.79)  
 R/R 29 (44.62) 30 (42.86) 1.74 (0.52-5.81) 15  (40.54) 12 (31.58) 3.75 (0.64-22.04) 
 R/P+R/R 60 (92.31) 61 (87.14) 1.77 (0.56-5.59) 35 (94.59) 32 (84.21) 3.28 (0.62-17.44) 
Menopausal 
status 
Genotype Cases; n (%) 
n=66 
Controls; n (%) 
n=38 
OR (95% CI) Cases; n (%) 
n=70 
Controls; n (%) 
n=59 
OR (95% CI) 
Post 5 (7.58) 3 (7.89)  2 (2.86) 4 (6.78)  
 R/R 28 (42.42) 17 (44.74) 0.99 (0.21-4.67) 39 (55.71) 23 (38.98) 3.39 (0.58-19.99) 
 R/P+R/R 61 (92.42) 35 (92.11) 1.05 (0.24-4.64) 68 (97.14) 55 (93.22) 2.47 (0.44-14.01) 
P/P 
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3.2.2.3. Distribution of the p21 Codon 31 Genotype 
Table 3.4 shows the distribution of the p21 codon 31 genotypes in the age-matched 
controls and breast cancer patients. Because the frequency of the p21 codon 31 
Arg/Arg genotype was very low (<5) the combination of Arg/Arg and Ser/Arg 
genotypes was used and determined to have an increased risk for breast cancer with a 
crude odds ratio of 1.15 (95% CI=0.75-1.76) for all subjects. The crude odds ratios 
for the whole group were 0.64 (95% CI=0.12-3.52) for the Ser/Ser genotype (serves 
as the reference group), 1.13 (95% CI=0.73-1.75) for the Ser/Arg genotype, and 1.57 
(95% CI=0.28-8.64) for the Arg/Arg genotype. The crude odds ratios for 
premenapousal women were 0.55 (95% CI=0.05-6.17) for the Ser/Ser genotype, 0.95 
(95% CI=0.50-1.81) for the Ser/Arg genotype, and 0.99 (95% CI=0.53-1.85) for the 
combination of Arg/Arg and Ser/Arg genotypes. The crude odds ratios for 
postmenopausal women were 0.76 (95% CI=0.07-8.47) for the Ser/Ser genotype, 
1.22 (95% CI=0.66-2.25) for the Ser/Arg genotype, and 1.22 (95% CI=0.67-2.23) for 
the combination of Arg/Arg and Ser/Arg genotypes. 
The adjusted odds ratios for the whole group were 3.70 (95% CI=0.33-41.66) for the 
Arg/Arg genotype, 1.03 (95% CI=0.58-1.82) for the Ser/Arg genotype and 1.10 
(95% CI=0.63-1.92) for the combination of Arg/Arg and Ser/Arg genotypes. In the 
premenopausal or postmenopausal groups, the odds ratios for the Arg/Arg genotype 
were not meaningful, and for the combination of Arg/Arg and Ser/Arg genotypes the 
odds ratio was 1.40 (95% CI=0.66-2.96) and 0.62 (95% CI=0.24-1.63) for post and 
premenopausal groups respectively. 
 
3.2.2.4. Distribution of p21 Genotypes According to BMI 
Table 3.5 summarizes the results of the distribution of the p21 codon 31 genotypes 
stratified according to BMI in cases and controls. Although there is increased 
association between breast cancer risk and combined Arg/Arg and Ser/Arg genotype 
frequencies among the subjects with BMI value below 27.40, the association is not 
significantly high (OR=1.32, 95% CI=0.71-2.45). A stronger association between 
breast cancer risk and the combination of Arg/Arg and Ser/Arg genotypes is present 
in the postmenopausal group (OR=2.59, 95% CI=0.96-7.01). Among the subjects 
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with BMI value above 27.40, there was no association between breast cancer risk and 
the combination of the Ser/Arg and Arg/Arg genotypes.  
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Table 3.4. Distribution of the p21 Codon 31 Genotypes Stratified According to Menopausal Status in the Age-matched Control and Breast 
Cancer Patients. 
Menopausal status Genotype Cases; n (%), n=322 Controls; n (%), n=246 Crude OR  95% CI Adjusted ORa 95% CI 
All S/S 259 (80.43) 203 (82.52) 0.64 (0.12-3.52) 1.00b 
 S/R 59 (18.32) 41 (16.67) 1.13 (0.73-1.75) 1.03 (0.58-1.82) 
 R/R 4 (1.24) 2 (0.81) 1.57 (0.28-8.64) 3.70 (0.33-41.66) 
 S/R+R/R 63 (19.57) 43 (17.48) 1.15 (0.75-1.76) 1.10 (0.63-1.92) 
Menopausal status Genotype Cases; n (%), n=133 Controls; n (%), n=121 Crude OR  95% CI Adjusted ORc 95% CI 
Pre S/S 108 (81. 20) 98 (80.99) 0.55 (0.05-6.17) 1.00b 
 S/R 23 (17.29) 22 (18.18) 0.95 (0.50-1.81) 0.58 (0.21-1.56) 
 R/R 2 (1.50) 1 (0.82) 1.81 (0.16-20.33) 1.28 (0.091-17.96) 
 S/R+R/R 25 (18.80) 23 (19.01) 0.99 (0.53-1.85) 0.62 (0.24-1.63) 
Menopausal status Genotype Cases; n (%), n=184 Controls; n (%), n=117 Crude OR  95% CI Adjusted ORc 95% CI 
Post S/S 147 (79.89) 97 (82.91) 0.76 (0.07-8.47) 1.00b 
 S/R 35(19.02) 19 (16.24) 1.22 (0.66-2.25) 1.34 (0.63-2.86) 
 R/R 2 (1.09) 1 (0.85) 1.32 (0.12-14.75) 128.298 (0.00-Exp)d 
 S/R+R/R 37 (20.11) 20 (17.09) 1.22 (0.67-2.23) 1.40 (0.66-2.96) 
 
a) Adjustment is according to menopausal status, age, age at menarche, age at full-term pregnancy, number of children, family history of breast cancer,  and smoking. 
b) Reference group 
c) Adjustment is according to age, age at menarche, age at full-term pregnancy, number of children, family history of breast cancer,  and smoking. 
d) Exp means exponential. R/R genotype carrying individuals were too low to calculate adjusted OR.  
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Table 3.5. Distribution of the p21 Codon 31 Genotype Stratified According to BMI in Cases and Controls 
 
Low BMI (<27.40) High BMI (≥27.40) 
Menopausal 
status  
Genotype Cases; n (%) 
n=153 
Controls; n 
(%)  
n=120 
OR (95% CI) Cases; n (%) 
n=124 
Controls (%) 
n=108 
OR (95% CI) 
All  S/S 121 (79.08%) 100 (83.33%)  104 (83.87%) 87 (80.56%)  
 S/R+R/R 32 (20.92%) 20 (16.67%) 1.32 (0.71-2.45) 20 (16.13%) 21 (19.44%) 0.80 (0.41-1.57) 
Menopausal 
status 
Genotype Cases; n (%) 
n=78 
Controls; n 
(%)  
n=74 
OR (95% CI) Cases; n (%) 
n=39 
Controls (%) 
n=43 
OR (95% CI) 
Pre  S/S 67 (85.90%) 60 (81.08%)  31 (79.49%) 34 (79.07%)  
 S/R+R/R 11 (14.10%) 14 (18.92) 0.70 (0.30-1.67) 8 (20.51%) 9 (20.93%) 0.97 (0.33-2.84) 
Menopausal 
status 
Genotype Cases; n (%) 
n=75 
Controls; n 
(%)  
n=46 
OR (95% CI) Cases; n (%) 
n=85 
Controls (%) 
n=65 
OR (95% CI) 
Post  S/S 54 (72.00%) 40 (86.96%)  73 (85.88%) 53 (81.54%)  
 S/R+R/R 21 (28.00%) 6 (13.04%) 2.59 (0.96-7.01) 12 (14.12%) 12 (18.46%) 0.73 (0.30-1.74) 
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3.2.2.5. Combined Analysis of p21 and p53 for Breast Cancer Risk  
Combined analysis of the p53 codon 72 Arg/Arg genotype and the p21 codon 31 
Arg/Arg or Ser/Arg genotypes was carried out (Table 3.6). The presence of the p53 
codon 72 Pro/Pro genotype together with the p21 codon 31 Ser/Ser genotype was 
designated as the reference group (OR=1.00). The combination of the relative risks 
of both genotypes showed a significantly increased risk for breast cancer (OR=2.66, 
95% CI=1.06-6.66). 
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Table 3.6. Combination of the p21 Codon 31 Genotype with the p53 Codon 72 Genotype for Breast Cancer Risk  
 
 
Genotype at risk P21  P53 Cases; n (%) 
n=267 
Controls; n (%) 
n=214 
Crude OR  
Nonea S/S P/P 13 (4.87%) 21 (9.81%) 1.00 
One S/S R/R 103 (38.57%) 68 (31.78%) 2.45 (1.15-5.21) 
 R/R+S/R P/P 3 (1.12%) 2 (0.93%) 2.42 (0.36-16.50) 
Two R/R+S/R R/R 28 (10.49%) 17 (7.94%) 2.66 (1.06-6.66) 
 
 
 
 
 
 
 
a) None group is a reference group  
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3.2.3.  Characteristics of the Subjects in the Greek Study Population 
The general characteristics of the Greek population are shown in Table 3.7. The only 
information available for Greek population is age and menopausal status. The mean 
age is 49.66 for the cases and 50.30 for the controls. 56% of the cases are 
premenopausal, while 44% are postmenopausal. For the control group the 
frequencies for pre- and postmenopausal subjects are 46.8% and 53.2%, respectively. 
Compared to the Turkish population, the premenopausal status of the Greek 
population OR is higher (OR=1.45, 95% CI=0.95-2.22) than the postmenopausal 
status value (OR=0.69, 95% CI=0.45-1.05), but the results are not statistically 
significant. 
 
3.2.4. Genotype Distributions in the Greek Population 
The distribution of the p53 codon 72 and p21 codon 31 genotypes in the Greek 
population is summarized in Tables 3.8 and 3.9, respectively.  
 
3.2.4.1. Distribution of the p53 Codon 72 Genotype  
The odds ratios for the p53 codon 72 genotypes are 7.93 (95% CI=0.95-65.98) for 
the Arg/Arg genotype, 6.50 (95% CI=0.77-54.64) for the Arg/Pro genotype, and 0.13 
(95% CI=0.02-1.05) for the Pro/Pro genotype (Table 3.8). Because the Pro/Pro 
frequency is less than 5%, the Pro/Pro and Arg/Pro genotypes were combined and 
the odds ratio is 0.74 (95% CI=0.46-1.20). From the OR calculations it is obvious 
that the genotype under the risk for breast cancer is Arg/Arg but the results are not 
statistically significant as in the Turkish population. When the subjects were grouped 
according to their menopausal status, the results were not statistically meaningful. 
For the premenopausal group, none of the odds ratios were significant. For the  
postmenopausal group, even the calculation of odds ratios was not possible because 
there was no postmenopausal case with Pro/Pro genotype. The odds ratio was 
calculated only for the combination of Arg/Pro and Pro/Pro genotypes was calculated 
but the result was not significant (OR= 0.57; 95% CI=0.28-1.17). 
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3.2.4.2. Distribution of the p21 Codon 31 Genotype  
The results for the p21 codon 31 genotype distributions in the Greek population are 
different from the Turkish population. Although the results are not significant, the 
Ser/Ser genotype seems to be a risk factor for breast cancer (OR=1.12, 95% CI=0.60-
2.09). Because there was no case with the Arg/Arg genotype in the population, we 
needed to combine the Arg/Arg genotype with the Ser/Arg genotype while 
calculating the odds ratio for the Ser/Ser genotype. In the case of Ser/Arg, the 
combination of Arg/Arg and Ser/Ser was taken as the non-risk group in order not to 
contradict the logic of the OR calculation of Ser/Ser genotype. The combination of 
the Arg/Arg and Ser/Arg genotypes had an odds ratio of 0.89 (95% CI=0.48-1.67) 
(Table 3.9).   
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Table 3.7. Characteristics of Subjects from the Greek Population  
 
Characteristics Cases (n; mean or %) Controls (n; mean or %) OR 95% CI 
Age n=92; 49.66 n=176; 50.301  
Premenopausal n=92;  56% n=87;  46.8% 1.45 (0.95-2.22) 
Postmenopausal n=72;   44% n=99;  53.2% 0.69 (0.45-1.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86 
Table 3.8. Distribution of the p53 Codon 72 Genotype Stratified According to Menopausal Status in the Age-matched Control and Breast Cancer 
Patients in the Greek Population. 
 Menopausal status Genotype Cases; n (%), n=138 Controls; n (%), n=138 Crude OR  95% CI 
All R/R 85 (61.59) 75 (54.35) 7.93 (0.95-65.98) 
 R/P 52 (37.68) 56 (40.58) 6.50 (0.77-54.64) 
 P/P 1 (0.72) 7 (5.07) 0.13 (0.02-1.05) 
 R/P+P/P 53 (38.41) 63 (45.65) 0.74 (0.46-1.20) 
Menopausal status Genotype Cases; n (%), n=74 Controls; n (%), n=63 Crude OR  95% CI 
Pre R/R 44 (59.46) 37 (58.73) 3.57 (0.36-35.76) 
 R/P 29 (39.19) 23 (36.51) 3.78 (0.37-38.82) 
 P/P 1 (1.35) 3 (4.76) 0.28 (0.03-2.81) 
 R/P+P/P 30 (40.54) 26 (41.27) 0.97 (0.49-1.92) 
Menopausal status Genotype Cases; n (%), n=72 Controls; n (%), n=74 Crude OR  95% CI 
Post R/R 35 (48.61) 37 (50.00) * 
 R/P 37 (51.39) 33 (44.59) * 
 P/P 0 (0.00) 4 (5.41) * 
 R/P+P/P 37 (51.39) 37 (50.00) 0.57 (0.28-1.17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Because the frequency of the P/P genotype for cases was 0.00%, we could not calculate the odds ratios for R/R, R/P, and P/P. 
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Table 3.9. Distribution of the p21 Codon 31 Genotypes Stratified According to Menopausal status in the Age-matched Control and Breast 
Cancer Patients in the Greek Population. 
 Menopausal status Genotype Cases; n (%), n=156 Controls; n (%), n=136 Crude OR  95% CI 
All S/S 132 (84.62) 113 (83.09) 1.12 (0.60-2.09)a 
 S/R 24 (15.38) 20 (14.71) 1.03 (0.54-1.96)b 
 R/R 0 (0.00) 3 (2.21) * 
 S/R+R/R 24 (15.38) 23 (16.91)  0.89 (0.48-1.67)
Menopausal status Genotype Cases; n (%), n=81 Controls; n (%), n=57 Crude OR  95% CI 
Pre S/S 66 (81.48) 47 (82.46) 0.94 (0.39-2.26)a 
 S/R 15 (18.52) 10 (17.54) 1.07 (0.44-2.58)b 
 R/R 0 (0.00) 0 (0.00) * 
 S/R+R/R 15 (18.52) 10 (17.54)  1.07 (0.44-2.58)
Menopausal status Genotype Cases; n (%), n=66 Controls; n (%), n=77 Crude OR  95% CI 
Post      S/S 58 (87.88) 65 (84.42) 1.34 (0.51-3.50)a 
 S/R 8 (12.12) 9 (11.69) 1.00 (0.36-2.75)b 
 R/R 0 (0.00) 3 (3.90) * 
 S/R+R/R 8 (12.12) 12 (15.58)  0.75 (0.29-1.96)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Because the frequency of R/R genotype was 0.00%, the combination of R/R and S/R was taken as non-risk group in calculating the OR for S/S genotype 
b) Non-risk group was taken as the combination of S/S and R/R, in calculating the OR for S/R genotype      
* Because the frequency of R/R genotype was 0.00% for the cases, we could not calculate the OR for R/R genotype  
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3.2.5. Genotype Distributions in the Turkish and Greek Populations 
The distribution of the p53 codon 72 and p21 codon 31 genotypes in the population 
containing both Turkish and Greek subjects is summarized in Tables 3.10 and 3.11, 
respectively.  
 
3.2.5.1. Distribution of the p53 Codon 72 Genotype 
The odds ratios for the p53 codon 72 genotypes are 2.35 (95% CI=1.25-4.41) for the 
Arg/Arg genotype, 1.89 (95% CI=1.01-3.56) for the Arg/Pro genotype, 0.43 (95% 
CI= 0.23-0.80), and 0.75 (95% CI=0.56-0.99) for the combination of the Pro/Pro and 
Arg/Pro genotypes. From the odds ratio calculations it is obvious that Arg/Arg 
genotype is strongly associated with breast cancer risk in a population of two Eastern 
Mediterranean countries. The Arg/Pro genotype was also found to be a significant 
risk factor for breast cancer in the combined population. When the subjects were 
grouped according to their menopausal status, premenopausal women with the 
Arg/Arg or Arg/Pro genotypes had a significantly increased risk for breast cancer 
susceptibility with odds ratio values of 2.70 (95% CI=1.12-6.54) and 2.55 (95% 
CI=1.05-6.19), respectively. The postmenopausal group did not give statistically 
significant results. 
 
3.2.5.2 . Distribution of the p21 Codon 31 Genotype  
The results for the p21 codon 31 genotype distributions are inconsistent in the 
combined population of the Turkish and Greek subjects when compared to the results 
of the Turkish and Greek populations alone (Table 3.11). 
 
 
 
 
 
 
 
 89 
Table 3.10. Distribution of the p53 Codon 72 Genotypes Stratified According to Menopausal status in the Age-matched Control and Breast 
Cancer Patients in the Turkish and Greek Populations. 
 
Menopausal status Genotype Cases (%), n=412 Controls (%), n=359 OR (95% CI) 
All R/R 217 (52.67) 163 (45.40) 2.35 (1.25-4.41) 
 R/P 178 (43.20) 166 (46.24) 1.89 (1.01-3.56) 
 P/P 17 (4.13) 30 (8.36) 0.43 (0.23-0.80) 
 R/P+P/P 195 (47.33) 196 (54.60) 0.75 (0.56-0.99) 
Menopausal status Genotype Cases (%), n=190 Controls (%), n=174 OR (95% CI) 
Pre R/R 96 (50.53) 80 (45.98) 2.70 (1.12-6.54) 
 R/P 86 (45.26) 76 (43.68) 2.55 (1.05-6.19) 
 P/P 8 (4.21) 18 (10.34) 0.37 (0.15-0.90) 
 R/P+P/P 94 (49.47) 94 (54.02) 0.83 (0.55-1.26) 
Menopausal status Genotype Cases (%), n=225 Controls (%), n=176 OR (95% CI) 
Post R/R 111 (49.33) 80 (45.45) 1.70 (0.67-4.28) 
 R/P 105 (46.67) 85 (48.30) 1.27 (0.50-3.21) 
 P/P 9 (4.00) 11 (6.25) 0.59 (0.23-1.49) 
 R/P+P/P 114 (50.67) 96 (54.55) 0.73 (0.49-1.09) 
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Table 3.11. Distribution of the p21 Codon 31 Genotypes Stratified According to Menopausal status in the Age-matched Control and Breast 
Cancer Patients in the Turkish and Greek Populations. 
 
Menopausal status Genotype Cases; n (%), n=478 Controls; n (%), n=382 OR (95% CI) 
All S/S 391 (81.80) 316 (82.72) 1.55 (0.41-5.81) 
 S/R 83 (17.36) 61 (15.97) 1.10 (0.77-1.58) 
 R/R 4 (0.84) 5 (1.31) 0.65 (0.17-2.43) 
 S/R+R/R 87 (18.20) 66 (17.28) 1.07 (0.75-1.52) 
Menopausal status Genotype Cases; n (%), n=214 Controls; n (%), n=178 OR (95% CI) 
Pre S/S 174 (81.31) 145 (81.46) 0.60 (0.05-6.68) 
 S/R 38 (17.76)  32 (17.98) 0.99 (0.59-1.66) 
 R/R 2 (0.93) 1 (0.56) 1.67 (0.15-18.57) 
 S/R+R/R 40 (18.69) 33 (18.54) 1.01 (0.61-1.68) 
Menopausal status Genotype Cases; n (%), n=250 Controls; n (%), n=194 OR (95% CI) 
Post S/S 205 (82.00) 162 (83.51) 2.53 (0.46-13.99) 
 S/R 43 (17.20) 28 (14.43)  1.21 (0.72-2.04) 
 R/R 2 (0.80) 4 (2.06) 0.40 (0.07-2.18) 
 S/R+R/R 45 (18.00) 32 (16.49) 1.11 (0.68-1.83) 
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3.2.6. P-value Calculation 
In this study, the chi-square test was used to calculate p-values and to test whether 
there is a relationship between p21 codon 31 and/or p53 codon 72 genotypes and the 
risk of developing breast cancer among subjects and the control groups. Table 3.12 
shows the p-values for the whole group and separately for the Turkish and Greek 
populations.  
 
Table 3.12. P-values for the p53 Codon 72 and p21 Codon 31 in the Turkish and 
Greek Populations (df=1). 
P-value 
Population 
p53 codon 72 p21 codon 31 
Turkish 0.027 0.527 
Greek  0.025* 0.723 
Whole 0.007 0.725 
 
* 2 cells with expected counts less than 5,0.  
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4. DISCUSSION 
Both p53 and p21 play important roles in cell cycle regulation. p53 is a transcription 
factor for p21 and p53 induces cell cycle arrest at the G1 phase by increasing p21 
expression upon DNA damage. Increased p21 concentration in cells mediates cell 
cycle arrest through cyclin-cdk inhibition. In order to understand human cancers it is 
critical to understand the potential roles and the interactions of these two key 
mediators of the cell cycle.  
Several factors make it important to analyze the effects of p53 and p21 
polymorphisms in breast cancer. First, although 20-40% of breast cancers have p53 
mutations, highly penetrant mutations are rare. Second, p21 mutations are also 
extremely rare in breast cancer and lastly, polymorphisms in both genes are quite 
common. It is important to analyze a potential gene-gene association between 
polymorphisms in the two genes because p21 is the major downstream component of 
the p53 tumor suppressor pathway. Such associations are reported for p53 codon 72 
and p21 codon 31 polymorphisms (Su et al. 2003). It was found that the genotype 
combination involving both the p53 codon 72 Pro allele and the p21 codon 31 Arg 
allele is associated with a particularly low expression of p21. 
For p53 only the codon 72 polymorphism appears to be significantly associated with 
the risk of breast cancer. The most common polymorphism in p21 is the Ser31Arg 
polymorphism in exon 2. This polymorphism has been studied in various cancers 
including breast cancer, but its significant role has not been investigated yet because 
of the contradictory results. 
The two polymorphic variants of p53 at codon 72 (Arg and Pro) are functionally 
distinct, and these differences may influence cancer risk or treatment (Dumont et al. 
2003). The p53 codon 72 polymorphism occurs in the proline-rich domain of p53, 
which is required for the growth suppression activity of p53 and also plays an 
important role in p53-mediated apoptosis (Thomas et al. 1999). The two 
polymorphic variations in codon 72 of p53 encodes an arginine amino acid with a 
positive-charged basic side chain or a proline residue with a non-polar aliphatic side 
chain (Langerod et al. 2002). Matlashewski et al. (1987) concluded that this is a 
nonconservative amino acid change and results in a structural change in the protein. 
Furthermore, Pro-72 p53-containing tumor cells appeared to grow more slowly and 
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were smaller than Arg-72 p53-containing tumor cells. Thomas et al. (1999) showed 
that p53-Pro is a stronger inducer of transcription than p53-Arg, whereas a p53 
Arg/Arg genotype induces apoptosis with faster kinetics and suppresses 
transformation more efficiently than the p53 Pro/Pro genotype. Moreover, E6 
proteins from both high-risk and low-risk HPV types are able to target p53Arg more 
efficiently than p53Pro for ubiquitin-mediated degradation and the majority of HPV-
associated tumors are homozygous for the p53Arg allele, whereas the majority of the 
comparable normal population was heterozygous.  
Further evidence for the importance of codon 72 containing region in p53 comes 
from Baptiste et al. (2002). It was shown that the proline-rich PXXP domain between 
residues 60-90 of p53 is required for cooperation with anti-neoplastic agents to 
promote apoptosis of tumor cells. 
p53 codon 72 polymorphism is important for the interaction of certain p53 mutants to 
form stable complexes with p73. When codon 72 encodes Arg, the ability of mutant 
p53 to bind p73 is enhanced. Formation of such complexes correlates with a loss of 
p73 DNA-binding capability, and consequently its ability to serve as a sequence-
specific transcriptional activator and an inducer of apoptosis (Marin et al. 2000). 
It was reported for squamous cell tumors and breast cancer cases that the occurrence 
of a p53 mutation was significantly more often found on the Arg72 allele than the 
Pro72 allele (Marin et al. 2000, Langerod et al. 2002). Tada et al. (2001) reported 
that p53 recessive mutants carrying the Arg allele can lead to decreased activation of 
p53 target genes through inactivation of p73. In addition, the arginine variant confers 
greater resistance to p73-dependent apoptosis and cytotoxicity than the equivalent 
proline form (Bergamaschi et al. 2003). 
Besides studies which try to understand the functional differences of two variants in 
p53 codon 72, there have been many studies conducted in order to investigate the 
association of p53 codon 72 polymorphism and cancer risk. 
The codon 31 of p21 is found in the area (sequences between amino acids 13 and 
56), which is almost perfectly conserved between mouse and human. This 
conservation of the amino acid sequences suggests that this region is important to the 
function of WAF1 as a CDK inhibitor (Hachiya et al. 1999). In addition, serine is an 
uncharged polar amino acid with a single hydroxy-1 side chain, whereas arginine is a 
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basic, positively charged amino acid with a seven-membered side chain. These 
observations raise the possibility that this polymorphism encodes functionally 
distinct proteins.  
Previous studies indicated a significant association of the Arg allele with human 
malignancies including breast tumor, sarcoma, rhabdomyosarcoma, neuroblastoma, 
prostate adenocarcinoma, colorectal cancer and lung cancer (Table 1.4). In those 
studies, the Arg allele was reported to occur more frequently in malignancy groups 
than in the healthy control group, suggesting that the Ser to Arg substitution results 
in some functional differences which contribute to tumorigenesis (Konishi et al. 
2000). However, further investigations are required for clarifying the association of 
the p21 polymorphism with tumorigenesis. 
In this study, we tried to investigate the effects of p53 codon 72 and p21 codon 31 
polymorphisms for increased susceptibility for breast cancer either independently or 
together. We performed the study in two different Mediterranean populations, 
Turkish and Greek. p53 and p21 polymorphisms were analyzed in case and control 
groups in both populations. 
p53 codon 72 polymorphism:  
Allelic frequencies of arginine (R) and proline (P) are in the Hardy-Weinberg 
equilibrium in the Turkish (R: 0.6, P: 0.4) and Greek (R: 0.7, P: 0.3) populations as 
well as in the whole group for the control subjects (R: 0.7, P: 0.3).     
In the Turkish population, p53 codon 72 the Arg/Arg genotype was found to be a 
significant risk factor for breast cancer development (OR=2.16; 95% CI=1.08-4.31). 
When we analyzed the subjects according to their menopausal status, it was shown 
that premenopausal cases with the Arg/Arg genotype have more risk for breast 
cancer (OR=2.59; 95% CI=0.97-6.93) than the postmenopausal cases (OR=1.37; 
95% CI=0.48-3.95). It was also shown that p53 Arg72Arg genotype is significantly 
associated with breast cancer risk in women with a high BMI (OR=3.86; 95% 
CI=1.12-13.26), but not in women with a low BMI (OR=1.46; 95% CI=0.58-3.67). 
When we grouped the subjects according to low or high BMI, their menopausal 
status did not show any significant effect on the association of breast cancer risk and 
the p53 Arg72Arg genotype. 
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In the Greek population, it is obvious that the genotype under risk for breast cancer is 
also Arg/Arg (OR=7.93; 95% CI=0.95-65.98) but the results are not statistically 
significant as in the Turkish population. The confidence interval was too wide to 
conclude that the result is statistically significant. Such limitation is related to the 
low number of subjects in the study population. Because of the low number of 
subjects, analyses according to menopausal status did not produce any statistically 
meaningful results. 
The Turkish and Greek populations are Eastern Mediterranean populations. We 
combined these populations and analyzed the p53 codon 72 polymorphism in relation 
to breast cancer susceptibility. It was found that the Arg/Arg genotype is a very 
strong risk factor for breast cancer for the combined study population (OR=2.35; 
95% CI=1.25-4.41). Even, the heterozygous genotype carrying only one Arg allele 
was significantly associated with breast cancer susceptibility (OR=1.89; 95% 
CI=1.01-3.56). When we analyzed the subjects according to their menopausal status, 
it was shown that premenopausal cases carrying the Arg allele at codon 72 have 
more risk for breast cancer (OR=2.70; 95% CI=1.12-6.54 for the Arg/Arg genotype 
and OR=2.55; 95% CI=1.05-6.19 for the Arg/Pro genotype) than the postmenopausal 
cases.  
The Turkish population can be accepted as of Caucasian origin and the results should 
be considered accordingly. Our observation of the association between p53 Arg/Arg 
genotype and breast cancer risk is in parallel with a previous study conducted in the 
Turkish population (Buyru et al., 2003). Although this study was carried on p53 
codon 72 polymorphism and breast cancer susceptibility, the number of subjects of 
our study is greater. In this study the authors analyzed only the genotype frequency 
and association of the p53 codon 72 polymorphism. But the number of breast cancer 
cases and control group was very low compared to our study. They also did not 
looked at all the established risk factors for breast cancer.  
Our result of increased association between Arg/Arg genotype and breast cancer risk 
in Greek population is in parallel with the study of Papadakis et al. (2000) on breast 
cancer in Greek population. Our study contradicts the lack of association in breast 
cancer that have been observed in a population of Caucasian-Slavic origin (Suspitsin 
et al. 2003). 
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p53 codon 72 polymorphism and cancer risk association have been studied in cancers 
other than breast (acute myeloid leukemia, bladder, cervical, gastric, laryngeal, lung, 
squamous cell carcinoma, vulval, and urothelial) and in different populations (Table 
1.5). The most studied cancer is cervical cancer. Positive results for Arg/Arg 
association were observed in Chinese, Indian, and in Israeli Jewish populations (Qie 
et al. 2002, Li et al. 2002, Nagpal et al. 2002, Saranth et al. 2002, and Arbel-Alon et 
al. 2002). There are also studies that show no association with cervical cancer in the 
Korean and Indian populations (Kim et al. 2001, Pillai et al. 2002). 
p21 codon 31 polymorphism:  
Allelic frequencies of serine (S) and arginine (R) are in the Hardy-Weinberg 
equilibrium in the Turkish (R: 0.9, P: 0.1) and Greek (R: 0.9, P: 0.1) populations as 
well as in the whole group for the control subjects (R: 0.9, P: 0.1).     
For the p21 codon 31, the Arg/Arg or Ser/Arg genotypes were accepted as risk 
groups for breast cancer in our Turkish study population (OR=1.15; 95% CI=0.75-
1.76). Although the result is not statistically significant, there is a slight increase in 
association for breast cancer. When we consider the effect of BMI and menopausal 
status, we see that postmenopausal women with low BMI and Arg/Arg or Ser/Arg 
genotypes have an increased association for breast cancer (OR=2.59; 95% CI=0.96-
7.01), which is different from the p53 case.  
The results for the p21 codon 31 genotype distributions in the Greek population are 
different from the Turkish population. Although the results are not significant, the 
Ser/Ser genotype seems to be a risk factor for breast cancer (OR=1.12, 95% CI=0.60-
2.09). 
In the study group of both Turkish and Greek subjects, the analysis of p21 codon 31 
genotype distributions did not reveal consistent results. Neither we could determine 
the risk group for breast cancer nor we obtained significant associations between 
breast cancer susceptibility and p21 codon 31 genotypes. 
Keshava et al. (2002) conducted a study on the association between p21 codon 31 
polymorphism and breast cancer risk in three different populations; Caucasians, 
African-American, and Latinas. In this study, the Ser allele was found to be the 
minor allele and the individuals carrying Ser at p21 codon 31 were analyzed as the 
risk group  for breast cancer risk. Although, an association for Ser variant in African-
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Americans (OR=2.32; 95% CI=0.66-5.60) and Latinas (OR=2.22; 95% CI=0.71-
6.89) was reported, no association was found in Caucasians. Ser variant association 
seems parallel to our results for the Greek population (OR=1.12; 95% CI=0.60-2.09). 
Another point that should be discussed is the confidence interval that they accepted 
as significant. In our study we accepted the results as statistically significant if the 
confidence interval does not include 1.00 and this is the accepted method for most of 
the studies. Lukas et al. (1997) also reported no association of p21 codon 31 
polymorphism and breast cancer risk but in American population. 
Risk association studies for p21 codon 31 polymorphism have been studied in 
different cancers and populations (Table 1.4). Association for the Arg allele was 
found to be significant for endometrial cancer in the Japanese and American 
populations (Hachiya et al. 1999, Lukas et al. 1997) and non-significant in the 
Taiwanese population (Hsieh et al. 2001). Significant increase in Arg allele 
frequency was also reported for lung cancer in the Swedish population (Sjalander et 
al. 1996). Non-significant increase in Arg allele was reported for head and neck 
carcinoma and prostate adenocarcinoma in American population (Facher et al. 1997). 
The p21 codon 31 polymorphism is not correlated to cancer susceptibility in all 
previous studies (Li et al. 1995, Su et al. 2003, Shih et al. 2000, Sun et al. 1995, 
Lukas et al. 1997, Konishi et al. 2000). 
Combined analysis of p21 (codon 31) and p53 (codon 72) polymorphisms:  
In our study, the combination of p53 Arg72Arg and p21 Arg31Arg or Ser31Arg 
genotypes showed a statistically significant potential association between the two 
genes and a risk for breast cancer development (OR=2.66; 95% CI=1.06-6.66). 
Interestingly, there was statistically significant association for the p53 high risk 
genotype Arg72Arg and the p21 non-risk genotype Ser31Ser (OR=2.45; 95% 
CI=1.15-5.21).  
Previously, two studies examined a potential association between common 
polymorphisms in p53 and p21 in relation to breast cancer (Powell et al. 2002, 
Keshava et al. 2002). Although, Powell et al. (2002) studied the effects of different 
polymorphisms of both p53 and p21 in breast cancer, the combined effect of the 
polymorphisms was not analysed. Keshava et al. (2002) looked for association 
between p21 Ser variant and p53 1-2-1 haplotype, but no gene-gene association was 
found. 
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P-value calculation:  
P-values smaller than 0.05 (α=0.05) were accepted as significant. Consistent with the 
odds ratio and confidence interval calculations, it was found that there is a 
relationship between the p53 codon 72 genotypes and the risk of developing breast 
cancer among subjects and the control groups in the Turkish and whole populations. 
P-value for the p53 codon 72 genotypes in the Greek population was also less than 
0.05 (0.025), but there was count values less than 5. This means that even if the p-
value is significant for the given data, the results should be interpreted with caution. 
  
Established risk factors:  
Family history of breast cancer is the best studied and most significant risk factor for 
breast cancer development (Vogelstein et al. 2002). When stratification according to 
family history of breast cancer was carried out in our Turkish study population, it 
was shown that family history of breast cancer is very strongly associated with breast 
cancer risk (OR=6.72; 95% CI=2.97-15.22). 
Early age at menarche, late age at first full term pregnancy, and late age at 
menopause, which are all associated with increased exposure to endogenous 
estrogens, increase the risk of developing breast cancer. Generally, cancer is a 
disease of late age, reflecting accumulation of mutations that eventually lead to 
tumorigenesis. Therefore, increasing age is also an important parameter for breast 
cancer risk. The case group had slightly earlier age at menarche than the control 
group. In order to determine the effect of early age at menarche on breast cancer risk 
in our population, we selected the group of subjects having age at menarche less than 
14 years (Vogelstain et al. 2002) as a risk group and carried out regression analysis. 
Age at menarche less than 14 significantly increased the susceptibility for breast 
cancer (OR=1.55; 95% CI=1.12-2.14). When we analyzed the Turkish study 
population for the other established risk factors, the results were as expected. The 
breast cancer patients were older than the control subjects. In addition, the cases had 
later age at first live birth and less number of children compared to the controls. In 
addition, when compared with the control group, a statistically significant number of 
breast cancer patients were postmenopausal (OR=1.47; 95% CI=1.08-2.00). 
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In our Turkish study population, we tried to investigate whether smoking status has 
any implications on breast cancer risk. Consistent with the earlier studies (Braga et 
al. 1996, Garcia-Closas et al. 1999) no risk assessment was found related to smoking 
for breast cancer susceptibility (OR=0.89; 95% CI=0.62-1.28). However, Terry et al. 
(2002) suggested that smoking does not decrease the risk of breast cancer and indeed 
suggested that there may be an increased breast cancer risk with smoking of long 
duration, smoking before a first-full term pregnancy, and passive smoking. These 
findings require confirmation in future studies. 
Another parameter that might affect the susceptibility for breast cancer is BMI (Ursin 
et al. 1995). Although being overweight (high BMI) during early adult life has been 
associated with a lower incidence of premenopausal breast cancer (Wrensch et al. 
2003), weight gain after age 18 is associated with a significantly increased risk of 
postmenopausal breast cancer (DeVita et al. 2001, Radimer et al. 1993). In parallel 
with the positive association studies, we found that p53 Arg72Arg genotype is 
significantly associated with breast cancer risk in women with a high BMI 
(OR=3.86; 95% CI=1.12-13.26). 
We performed direct analysis for menopausal status, BMI, age at menarche, family 
history of breast cancer, and smoking status on breast cancer risk. It was possible to 
analyze the overall effect of these factors together with the first pregnancy age and 
the number of children by examining the crude and adjusted odds ratios. Adjusted 
odds ratio is the odds ratio of only a defined parameter and the effect of the above 
factors is excluded. For p53 Arg/Arg genotype the crude and adjusted odds ratios 
together with 95% CI are 2.16 (1.08-4.31) and 1.88 (0.69-5.10), respectively. When 
adjusted we see a considerable decrease in the OR, which means the effect of 
variables other than Arg/Arg inheritance may have an important effect on breast 
cancer development.       
 
To our knowledge, this is the first genetic study to show associations between the 
genotype frequencies of p21 codon 31 and p53 codon 72 polymorphisms and the 
established breast cancer risk factors in the Turkish population. This is also the first 
study to show a combined effect of p21 codon 31 and p53 codon 72 polymorphisms 
on breast cancer risk. 
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5. CONCLUSION AND FUTURE PERSPECTIVES 
 
The findings of our study are as follows: 
1. In the Turkish study population, Arg72Arg genotype of p53 is in strong 
association with breast cancer development, especially among the subjects 
with increased BMI. 
2. The combined effect of p21 codon 31 Arg/Arg and Ser/Arg genotypes has a 
slightly increased susceptibility for breast cancer in the Turkish population. 
3. There is a prominent increase in breast cancer risk for the individuals 
carrying both high-risk allelic variants of p53 codon 72 and p21 codon 31 
polymorphisms in the Turkish population. 
4. In the combined population of the Turkish and Greek subjects, individuals, 
especially the premenopausal subjects, carrying Arg allele at codon 72 of 
p53 have a significantly increased risk for breast cancer susceptibility. 
5. Generally recognized breast cancer risk factors such as family history of 
breast cancer, earlier age at menarche, and postmenopausal state contributed 
to a higher risk for breast cancer in the Turkish population. Smoking status 
does not seem to have any effect on breast cancer susceptibility. Although 
BMI increased the risk of p53 Arg72Arg genotype for breast cancer 
susceptibility, it does not have any contribution alone or together with p21 
codon 31 polymorphism. Other established risk factors for breast cancer 
such as increasing age, late age at first full term pregnancy, less number of 
children might be also involved in the increased susceptibility for breast 
cancer. 
6. The studies we performed with Greek population did not reveal a significant 
association with the studied polymorphisms and breast cancer risk. 
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Further analysis of these polymorphisms in large and diverse populations is 
necessary to confirm the previous results. 
p53 and p21 mutational status in relation to p53 and p21 expression levels and 
polymorphisms could be evaluated in order to understand better the interaction 
between p53 and p21 genes. 
The effects of allelic differences in p53 codon 72 and p21 codon 31 on the gene-gene 
interactions can be investigated to understand the underlying mechanisms.  
Because p53 is a critical regulator of apoptosis, effect of p53 polymorphism on drug 
response and treatment can be studied.  
Possible interactions with other genetic variations such as polymorphisms in steroid 
hormone metabolism genes and carcinogen metabolism genes and with DNA 
damage responsive elements (i.e. BRCA genes) can be analyzed and the results of 
the combined effects of these variations can be evaluated with breast cancer risk. 
Better defined groups for the relation of the polymorphisms and breast cancer 
etiology (e. i. staging, progression, receptor status) may give us valuable results. 
Furthermore, such kind of studies may help for early diagnosis of breast cancer by 
determining the risk factors that individuals carry. 
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7. APPENDIX 
The coding of the risk and non-risk groups of every table in the results part (Chapter 3). Cases: Breast cancer patients. Controls: Non-breast 
cancer subjects. 
 
Table 3.1. General Characteristics of the Subjects in the Turkish Study Population 
 
 
  
Characteristics 
Variable 1* 
Case/Control 
Variable 2 
 
OR (95%CI) 
Family history of breast 
cancer(FHBC) Case: 1, Control: 0 FHBC present: 1, FHBC absent: 0 6.72 (2.97-15.22) 
BMI≥27.40 Case: 1, Control: 0 [BMI≥27.40]: 1, [BMI<27.40]: 0 0.90 (0.65-1.24) 
Age at menarche(AM)<14 Case: 1, Control: 0 [AM<14]: 1, [AM≥14]: 0 1.55 (1.12-2.14) 
Premenopausal Case: 1, Control: 0 Pre: 1, Post: 0 0.68 (0.50-0.93) 
Postmenopausal Case: 1, Control: 0 Post: 1, Pre: 0 1.47 (1.08-2.00) 
Smoking Case: 1, Control: 0 Smoker: 1, Non-smoker: 0 0.89 (0.62-1.28) 
 
 
 
 
 
 
 
 
 
* Variable 1; cases: 1, controls: 0 
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Table 3.2. Distribution of the p53 Codon 72 Genotypes in the Age-matched Control and Breast Cancer Patients 
* 
Menopausal 
status 
Genotype Variable 2 Crude OR  95% CI Variable 2 Adjusted ORa 95% CI 
All R/R R/R: 1, P/P: 0 2.16 (1.08-4.31) R/R: 1, P/P: 0 1.88 (0.69-5.10) 
 R/P R/P: 1, P/P: 0 1.65 (0.83-3.27) R/P: 1, P/P: 0 1.62 (0.60-4.35) 
 P/P P/P: 1, R/R:0 0.46 (0.23-0.93) P/P: 0 (reference) 1.00 
 R/P+P/P R/P, P/P: 1, R/R:0    0.71 (0.50-1.02)
Pre R/R R/R: 1, P/P: 0 2.59 (0.97-6.93) R/R: 1, P/P: 0 2.60 (0.59-11.38) 
 R/P R/P: 1, P/P: 0 2.30 (0.87-6.09) R/P: 1, P/P: 0 2.26 (0.53-9.61) 
 P/P P/P: 1, R/R:0 0.39 (0.14-1.03) P/P: 0 (reference) 1.00 
 R/P+P/P R/P, P/P: 1, R/R:0    0.78 (0.46-1.32)
Post R/R R/R: 1, P/P: 0 1.37 (0.48-3.95) R/R: 1, P/P: 0 1.57 (0.29-8.62) 
 R/P R/P: 1, P/P: 0 1.02 (0.36-2.91) R/P: 1, P/P: 0 1.27 (0.23-6.87) 
 P/P P/P: 1, R/R:0 0.73 (0.25-2.09) P/P: 0 (reference) 1.00 
 R/P+P/P R/P, P/P: 1, R/R:0    0.74 (0.45-1.22)
 
 
* Variable 1; cases: 1, controls: 0  
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Table 3.3. Distribution of the p53 Codon 72 Genotypes Stratified According to BMI in Cases and Controls 
* 
                                                  Low BMI (<27.40)                                                            High BMI (≥27.40) 
Menopausal 
status Genotype Variable 2 OR (95% CI) Variable 2 OR (95% CI) 
All      P/P Reference reference
 R/R R/R: 1, P/P: 0 1.46 (0.58-3.67) R/R: 1, P/P: 0 3.86 (1.12-13.26) 
 R/P+R/R R/P, R/R: 1, P/P:0 1.51 (0.63-3.65) R/P, R/R: 1, 
P/P:0 
2.96 (0.90-9.77) 
Pre      P/P Reference reference
 R/R R/R: 1, P/P: 0 1.74 (0.52-5.81) R/R: 1, P/P: 0 3.75 (0.64-22.04) 
 R/P+R/R R/P, R/R: 1, P/P:0 1.77 (0.56-5.59) R/P, R/R: 1, 
P/P:0 
3.28 (0.62-17.44) 
Post      P/P Reference reference
 R/R R/R: 1, P/P: 0 0.99 (0.21-4.67) R/R: 1, P/P: 0 3.39 (0.58-19.99) 
 R/P+R/R R/P, R/R: 1, P/P:0 1.05 (0.24-4.64) R/P, R/R: 1, 
P/P:0 
2.47 (0.44-14.01) 
 
* Variable 1; cases: 1, controls: 0 
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Table 3.4. Distribution of the p21 Codon 31 Genotypes in the Age-matched Control and Breast Cancer Patients 
* 
 
Menopausal 
status Genotype Variable 2
 Crude OR  95% CI Variable 2 Adjusted ORa 95% CI 
All S/S S/S: 1, R/R: 0 0.64 (0.12-3.52) S/S: 0 (reference) 1.00 
 S/R S/R: 1, R/R: 0 1.13 (0.73-1.75) S/R: 1, S/S: 0 1.03 (0.58-1.82) 
 R/R R/R: 1, S/S: 0 1.57 (0.28-8.64) R/R: 1, S/S: 0 3.70 (0.33-41.66) 
 S/R+R/R S/R, R/R: 1, S/S: 0 1.15 (0.75-1.76) S/R, R/R: 1, S/S: 0 1.10 (0.63-1.92) 
Pre S/S S/S: 1, R/R: 0 0.55 (0.05-6.17) S/S: 0 (reference) 1.00 
 S/R S/R: 1, R/R: 0 0.95 (0.50-1.81) S/R: 1, S/S: 0 0.58 (0.21-1.56) 
 R/R R/R: 1, S/S: 0 1.81 (0.16-20.33) R/R: 1, S/S: 0 1.28 (0.091-17.96) 
 S/R+R/R S/R, R/R: 1, S/S: 0 0.99 (0.53-1.85) S/R, R/R: 1, S/S: 0 0.62 (0.24-1.63) 
Post S/S S/S: 1, R/R: 0 0.76 (0.07-8.47) S/S: 0 (reference) 1.00 
 S/R S/R: 1, R/R: 0 1.22 (0.66-2.25) S/R: 1, S/S: 0 1.34 (0.63-2.86) 
 R/R R/R: 1, S/S: 0 1.32 (0.12-14.75) R/R: 1, S/S: 0 128.298 (0.00-EXP) 
 S/R+R/R S/R, R/R: 1, S/S: 0 1.22 (0.67-2.23) S/R, R/R: 1, S/S: 0 1.40 (0.66-2.96) 
 
  
 
 
 
 
 
 
 
 
 
 
 
  * Variable 1; cases: 1, controls: 0 
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Table 3.5. Distribution of the p21 Codon 31 Genotype Stratified According to BMI in Cases and Controls 
* 
 Low BMI (<27.40) High BMI (≥27.40) 
Menopausal 
status  Genotype Variable 2 OR (95% CI) Variable 2 OR (95% CI) 
All  S/S reference  reference  
 S/R+R/R S/R, R/R: 1, S/S: 0 1.32 (0.71-2.45) S/R, R/R: 1, S/S: 0 0.80 (0.41-1.57) 
Menopausal 
status 
Genotype  OR (95% CI)  OR (95% CI) 
Pre  S/S reference  reference  
 S/R+R/R S/R, R/R: 1, S/S: 0 0.70 (0.30-1.67) S/R, R/R: 1, S/S: 0 0.97 (0.33-2.84) 
Menopausal 
status 
Genotype  OR (95% CI)  OR (95% CI) 
Post  S/S reference  reference  
 S/R+R/R S/R, R/R: 1, S/S: 0 2.59 (0.96-7.01) S/R, R/R: 1, S/S: 0 0.73 (0.30-1.74) 
 
 
 * Variable 1; cases: 1, controls: 0  
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Table 3.6. Combination of the p21 Codon 31 Genotype with the p53 Codon 72 Genotype for Breast Cancer Risk  
* 
 
Genotype at risk P21 P53 Variable 2 Crude OR  
None S/S   P/P reference 1.00
One S/S R/R S31S/ R72R: 1; S31S/ P72P:01 2.45 (1.15-5.21) 
 R/R+S/R P/P R31R+S31R/ P72P:1;  S31S/ P72P:01 2.42 (0.36-16.50) 
Two R/R+S/R R/R R31R+S31R/ R72R: 1; S31S/ P72P:01 2.66 (1.06-6.66) 
 
 
 
 
 
 
 
 
 * Variable 1; cases: 1, controls:0 
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Table 3.7. Characteristics of Subjects from the Greek Population  
 
Characteristics Variable 1 (cases/controls) Variable 2 OR 95% CI 
Premenopausal Cases: 1, controls: 0  Pre: 1, post: 0 1.45 (0.95-2.22) 
Postmenopausal Cases: 1, controls: 0 Post: 1, pre: 0  0.69 (0.45-1.05) 
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Table 3.8. Distribution of the p53 Codon 72 Genotype in the Age-matched Control and Breast Cancer Patients in the Greek Population 
 
 Menopausal 
status 
Genotype  Variable 1
(cases/controls) 
Variable 2 Crude OR  95% CI 
All R/R Cases: 1, controls: 0  R/R: 1, P/P: 0 7.93 (0.95-65.98) 
 R/P Cases: 1, controls: 0  R/P: 1, P/P: 0 6.50 (0.77-54.64) 
 P/P Cases: 1, controls: 0  P/P: 1, R/R:0 0.13 (0.02-1.05) 
 R/P+P/P Cases: 1, controls: 0  R/P, P/P: 1, R/R:0 0.74 (0.46-1.20) 
Pre R/R Cases: 1, controls: 0  R/R: 1, P/P: 0 3.57 (0.36-35.76) 
 R/P Cases: 1, controls: 0  R/P: 1, P/P: 0 3.78 (0.37-38.82) 
 P/P Cases: 1, controls: 0  P/P: 1, R/R:0 0.28 (0.03-2.81) 
 R/P+P/P Cases: 1, controls: 0  R/P, P/P: 1, R/R:0 0.97 (0.49-1.92) 
Post     R/R * * *
R/P * * *
P/P * * *
 R/P+P/P Cases: 1, controls: 0  R/P, P/P:1, R/R:0 0.57 (0.28-1.17) 
     
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Because the frequency of P/P genotype for cases was 0.00%, we could not calculate the odds ratios for R/R, R/P, and P/P.  
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Table 3.9. Distribution of the p21 Codon 31 Genotypes in the Age-matched Control and Breast Cancer Patients in the Greek Population 
 
Menopausal status Genotype Variable 1 
(cases/controls) 
Variable 2 Crude OR  95% CI 
All S/S Cases: 1, controls: 0  S/S: 1; R/R, S/R: 0  1.12 (0.60-2.09)a 
S/R Cases: 1, controls: 0  S/R: 1; S/S, R/R: 0  1.03 (0.54-1.96)b 
R/R * * * 
S/R+R/R Cases: 1, controls: 0  S/R, R/R: 1, S/S: 0 0.89 (0.48-1.67) 
Pre S/S Cases: 1, controls: 0  S/S: 1; R/R, S/R: 0  0.94 (0.39-2.26)a 
S/R Cases: 1, controls: 0  S/R: 1; S/S, R/R: 0  1.07 (0.44-2.58)b 
R/R Cases: 1, controls: 0  * * 
S/R+R/R Cases: 1, controls: 0  S/R, R/R: 1, S/S: 0 1.07 (0.44-2.58) 
Post  S/S Cases: 1, controls: 0  S/S: 1; R/R, S/R: 0  1.34 (0.51-3.50)a 
S/R Cases: 1, controls: 0  S/R: 1; S/S, R/R: 0  1.00 (0.36-2.75)b 
R/R Cases: 1, controls: 0  * * 
S/R+R/R Cases: 1, controls: 0  S/R, R/R: 1, S/S: 0 0.75 (0.29-1.96) 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Because the frequency of R/R genotype was 0.00%, the combination of R/R and S/R was taken as non-risk group in calculating the OR for S/S genotype 
b) Non-risk group was taken as the combination of S/S and R/R, in calculating the OR for S/R genotype      
* Because the frequency of R/R genotype was 0.00% for the cases, we could not calculate the OR for R/R genotype  
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Table 3.10. Distribution of the p53 Codon 72 Genotypes in the Age-matched Control and Breast Cancer Patients in the Turkish and Greek 
Populations. 
 
Menopausal status Genotype Variable 1 
(cases/controls) 
Variable 2 OR (95% CI) 
All R/R Cases: 1, controls: 0 R/R: 1, P/P: 0 2.35 (1.25-4.41) 
 R/P Cases: 1, controls: 0 R/P: 1, P/P:0 1.89 (1.01-3.56) 
 P/P Cases: 1, controls: 0 P/P: 1, R/R:0 0.43 (0.23-0.80) 
 R/P+P/P Cases: 1, controls: 0 R/P: 1, P/P: 1, R/R:0 0.75 (0.56-0.99) 
Pre R/R Cases: 1, controls: 0 R/R: 1, P/P: 0 2.70 (1.12-6.54) 
 R/P Cases: 1, controls: 0 R/P: 1, P/P:0 2.55 (1.05-6.19) 
 P/P Cases: 1, controls: 0 P/P: 1, R/R:0 0.37 (0.15-0.90) 
 R/P+P/P Cases: 1, controls: 0 R/P: 1, P/P: 1, R/R:0 0.83 (0.55-1.26) 
Post R/R Cases: 1, controls: 0 R/R: 1, P/P: 0 1.70 (0.67-4.28) 
 R/P Cases: 1, controls: 0 R/P: 1, P/P:0 1.27 (0.50-3.21) 
 P/P Cases: 1, controls: 0 P/P: 1, R/R:0 0.59 (0.23-1.49) 
 R/P+P/P Cases: 1, controls: 0 R/P: 1, P/P: 1, R/R:0 0.73 (0.49-1.09) 
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Table 3.11. Distribution of the p21 Codon 31 Genotypes in the Age-matched Control and Breast Cancer Patients in the Turkish and Greek 
Populations. 
 
Menopausal status Genotype Variable 1 
(cases/controls) 
Variable 2 OR (95% CI) 
All S/S Cases: 1, controls: 0  S/S: 1; R/R: 0  1.55 (0.41-5.81) 
 S/R Cases: 1, controls: 0  S/R: 1; S/S: 0  1.10 (0.77-1.58) 
 R/R Cases: 1, controls: 0 R/R: 1, S/S:0 0.65 (0.17-2.43) 
 S/R+R/R Cases: 1, controls: 0  S/R, R/R: 1; S/S: 0 1.07 (0.75-1.52) 
Pre S/S Cases: 1, controls: 0  S/S: 1; R/R: 0  0.60 (0.05-6.68) 
 S/R Cases: 1, controls: 0  S/R: 1; S/S: 0  0.99 (0.59-1.66) 
 R/R Cases: 1, controls: 0  R/R: 1, S/S:0 1.67 (0.15-18.57) 
 S/R+R/R Cases: 1, controls: 0  S/R, R/R: 1; S/S: 0 1.01 (0.61-1.68) 
Post S/S Cases: 1, controls: 0  S/S: 1; R/R: 0  2.53 (0.46-13.99) 
 S/R Cases: 1, controls: 0  S/R: 1; S/S: 0  1.21 (0.72-2.04) 
 R/R Cases: 1, controls: 0  R/R: 1, S/S:0 0.40 (0.07-2.18) 
 S/R+R/R Cases: 1, controls: 0  S/R, R/R: 1; S/S: 0 1.11 (0.68-1.83) 
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